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Abstract 
 
 
Engineering a Multifunctional Scaffold for Spinal Cord Repair 
 
Noelle Comolli 
Anthony M Lowman, PhD 
 
 
 
Spinal cord injury (SCI) affects approximately 10,000 individuals in the United 
States every year. SCI occurs most commonly in young adults, leaving them seriously 
disabled for the remainder of their lives. Several potentially useful therapeutic strategies 
have emerged over the last decade including the use of scaffolds and bridges, delivery of 
neurotrophic factors, other therapeutic peptides and use of marrow stromal cells to 
promote neuronal regeneration and functional recovery. However, none of the current 
strategies have shown enough effect to move to clinical trials and no major efforts have 
been undertaken to test a combination of these strategies, which can potentially be 
synergistic, and lead to greater therapeutic effect. Therefore, a need exists to develop a 
multifunctional construct which can integrate multiple, promising therapeutic strategies.  
We propose to develop a novel, injectable scaffold containing stem cells (either 
adult messenchymal lineage or fetal neural lineage) and neurotrophic factors. The 
polymeric scaffold is a branched copolymer of poly (N-isopropylacrilamide) and 
poly(ethylene glycol) (PNIPAAm-PEG), which exhibits a phase transition typically 
between 29-320C.  We hypothesize that localized, sustained, simultaneous delivery of 
multiple therapeutic proteins into the CNS along with an injectable polymeric-cellular 
scaffold creates a synergistic effect by synchronously modulating the injured 
environment and activating different signaling pathways. The delivery of nuerotrophic 
 xii 
factors (specifically, NT-3 and BDNF) can be controlled by encapsulating them within 
biodegradable microparticles made from poly-lactic acid (PLA). By engineering this 
injectable hydrogel and cellular based scaffold to mimic the host tissues we can create a 
novel platform technology with applications in treatment of SCI and other tissue 
engineering applications.  
 1 
Chapter 1 Introduction and specific aims 
 
 
 
Spinal cord injury (SCI) affects approximately 10,000 individuals in the United States 
every year. SCI occurs most commonly in young adults, leaving them seriously disabled 
for the remainder of their lives. Apart from paralysis, patients of SCI suffer from 
additional disabilities including bladder, bowel and sexual dysfunction, and neuropathic 
pain syndromes. Several potentially useful therapeutic strategies have emerged over the 
last decade. These include delivery of neurotrophic factors and other therapeutic proteins, 
synthetic scaffolds and bridges, and use of stem cells to promote neuronal regeneration 
and functional recovery1. However, current strategies have yet to resolve the surgical 
difficulties of implantation, and none have seen the crossing of axons across their 
“bridge”.  A new method in which the scaffold can be injected, therefore providing a 
minimally invasive surgical technique, is desirable. The scaffold should also be 
multifunctional, in that is should provide not only a surface for cellular growth, but also a 
protected environment that adapts to the growing axons allowing them to grow into the 
scaffold, through it and back out in order to reconnect with their target cells.   
It is proposed that the use of a novel injectable, multifunctional scaffold, which upon 
injection to the spinal cord would provide not only mechanical support to the injury site 
but also provide a local sustained release of a combination of therapeutic proteins as well. 
The scaffold will therefore provide a protected area for the regeneration of injured axons 
by creating polymeric-cellular bridge. The proposed scaffold is made from a thermally 
responsive, injectable polymer, poly (N-isopropyl)-graft-poly (ethylene glycol) 
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(PNIPAAm-PEG), combined with neural precursor cells.  Below its LCST, typically 
around 29-32°C, the polymer forms a miscible solution with water, but above its LCST, it 
becomes hydrophobic, separating from water and forming a semi porous gel. This makes 
PNIPAAm-PEG an ideal candidate since it provides not only a minimally invasive 
surgical technique, but also a scaffold that is space filling. Since the polymeric scaffold is 
semiporous it can easily incorporate cell growth and can be engineered to match the 
mechanical properties of the native neuronal tissue. This is of great importance in the 
design, since as many failed attempts prior have shown, mechanical mismatch is a critical 
parameter in implant design. The incorporation of neural precursor cells provides a 
matrix of necessary growth factors, extra cellular matrix, and other support molecules for 
axon growth. The included precursor cells not only sprout axons themselves, but in the 
process also stimulate the injured host axons to grow. 
In order to provide a protected environment for axon growth, growth promoting 
trophic facts must be present and the limited contact with growth inhibitory molecules is 
necessary. Since the direct injection of these trophic factors, such as brain derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and vascular endothelial growth 
factor (VEGF), lead to flooding of the local tissue, which does not support growth, the 
inclusion of these trophic factors into the scaffold is proposed. Since the polymeric 
scaffold is hydrophilic it sufficiently traps the trophic factors within its matrix after 
injection, slowly releasing them to the local tissue. This therefore provides a mechanism 
to not only draw axons into the scaffold (where the trophic factors are localized) but the 
prolonged release allows a motivation for axons to exit the scaffold to the local tissue.  
Further control of the release can be achieved by incorporating the trophic factors within 
 3 
biodegradable microparticles. Microparticles can be made via a simple emulsion 
technology using poly-(lactic acid) (PLA), which has been shown to be biocompatible in 
other biomaterial applications. 
It is therefore hypothesized that simultaneous, sustained, localized delivery of 
multiple proteins into the CNS along with an injectable polymeric-cellular scaffold 
creates a synergistic therapeutic effect by synchronously modulating different 
biochemical pathways. Engineering this injectable hydrogel and cellular based scaffold to 
mimic the host tissues will lead to a novel platform technology with applications in 
treatment of SCI and other tissue engineering applications.  Specifically, the aims of this 
project were to: 
1. Synthesize and characterize microparticle drug delivery system. 
Biodegradable microparticles will be synthesized using a double-emulsion 
solvent extraction method, and characterized for size, morphology, 
encapsulation efficiency and release characteristics. 
2. Synthesize, characterize and mechanically optimize the scaffold system and 
assess the effect of the addition of microparticles on the scaffold. 
Scaffolds made from three different types of polymers will be made with 
microparticles (optimized from aim 1) incorporated. These scaffolds will 
then be characterized and mechanically optimized to match the stiffness of 
the spinal cord tissue. 
 
 
 
 4 
 
3. Characterize the in vitro cellular scaffold system. 
The most optimal scaffold of the three designed in aim 2 will be studied in 
this aim. The scaffold will be evaluated in vitro with cells and trophic 
factors to assess the polymer-cell viability as well as the trophic factor 
release.  
4. Characterize the in vivo cellular scaffold system in a rodent model of spinal cord 
injury. 
The polymeric scaffold optimized by aims 1,2 and 3 will be tested in vivo 
in a rodent model of spinal cord injury. These studies will focus on the 
safety of the polymer system in an animal model as well as the surgical 
feasibility of the design. 
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Chapter 2  Background 
 
 
2.1 Spinal cord injury  
 
2.1.1 The human spinal cord  
 The human spinal cord is simply an extension of the brain stem, made largely of 
nerve cells, glia cells (support cells) and blood vessels. Neurons, the basic component of 
the spinal cord, are specialized cells that are divided into two main parts, the cell body 
(soma) and its processes (axons and dendrites) where the electrochemical signal is 
transported (figure 2.1). The spinal cord tissue has a distinctive butterfly shape when seen 
in cross section (figure 2.2), which is known as the gray matter. The gray matter is where 
the intergration and processing of information occurs, while the surrounding white matter 
is where the axon are located.  The spinal cord is covered in a protective layer, known as 
the meninges. The outermost protective layer is known as the dura matter. Signals to the 
body enter and exit the spinal cord through the spinal nerves that can carry both motor 
and sensory signals.  
 
2.1.2 The injury 
Spinal cord injury (SCI) is defined as any damage to the spinal cord that results in 
a loss of function.  In most cases of SCI, the cord itself is still intact, however enough 
damage has occurred for a loss of some function. Spinal cord injury affects nearly 
250,000 Americans with an estimated additional 10,000 cases per year (NIH, 2001).  The 
vast majority of these cases are of young adults in their early twenties, leading to an 
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overwhelming financial burden. The estimated annual expenses for a SCI patient is 
$250,000 per year, with an annual national cost of $10 billion on medical and supportive 
care (NIH, 2001).  
A spinal cord injury is most commonly the result of a car accident, fall, gunshot 
or other accident (NIH, 2001). This leads to a contusion (compression) or a physical tear 
of the spinal cord. The immediate injury as a result of the trauma is irreversible and 
frequently results in severed axons and blood vessels 1. Following the injury the patient 
will most likely enter into spinal shock, a period lasting hours up to days where all, or 
almost all, spinal reflexes are absent 1, 2.  During spinal shock the spinal cord will swell to 
fill the entire spinal canal restricting blood flow and oxygen transport to the injury site. 
This results in a cascade of secondary damage that can extend the damage over a larger 
portion of the spinal cord thus injuring previously untouched axons and signal pathways 
2.  
  Secondary damage also includes the over stimulation of nerve synapses by 
releasing an excess of neurotransmitters 2. This creates a harsh environment for the intact 
neurons since apoptotic and other cell death signals are prevalent. The immune system in 
an attempt to repair the damage due to the SCI invades the area with macrophages and 
neutrophils that remove the dead cells and debris. This usually generates a fluid cyst, or 
hole, where the axons and neural tissue used to be2, 3 (figure 2.3). While the astrocytes 
and other glial cells proliferate after the SCI, they are not able to promote regeneration or 
growth and become “reactive astrocytes”. The collection of astrocytes and 
oligodendrocytes together create a boundary to reconnection of axons and their targets, 
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known as the glial scar 3, 4. The glial scar is believed to be one of the major hurdles to 
regeneration5-7.   
 
2.1.3 Current treatment options 
 Current treatment options for SCI are extremely limited since there is no 
regenerative treatment available.  The first goal is to stabilize the injured spine and 
prevent recompression on the injury site by a combination of surgery and physical braces 
for support.  Once the spine is stable, treatment of symptoms is the main priority. These 
include respiratory, bowel and bladder problems, as well as muscle spasms, pain, 
irregular blood pressure, blood clots and pressure sores. Other long term problems 
include sexual dysfunction and autonomic dysreflexia (where the reflex actions to simple 
stimuli are not controlled by the brain and can therefore be life threatening) 2, 8.  A 
potential treatment used in some hospitals is the immediate dosage of methylprendilosone 
to the injury site. This steroid can help to prevent some of the wave of secondary damage 
and therefore lessen the severity of the injury if given early enough 2, 8.  Many SCI 
patients are left with life altering complications.  
 
2.2 Spinal cord repair- what is required? 
 In order to successfully regenerate the lost tissue following spinal cord injury, a 
combination of things needs to occur. The damaged nerve cells need to be replaced or 
repaired; axons must navigate to their target cells and construct new synapses. It has been 
suggested that only a small percentage of the original axons need to be recovered in order 
to regain normal functions (reviewed in Batchelor & Howells, 2003)9. However, many 
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barriers exist in the injured spine that prevents this from happening. First, the presence of 
the glial scar and a cyst created from the injury impede the growth of cells and extension 
of axons1, 3, 5, 6, 9, 10. The high number of macrophages and cytotoxic signals present in the 
injury area prevent cell survival and limit regeneration.  
In order to a design to successfully regenerate function, it must create a more 
hospitable environment for cell growth. Regeneration strategies should also focus on 
filling the cavity, or cysts, created by the injury. If left alone, the cyst prevents growth of 
cells or axons, thus impeding recovery3. Many different strategies have been proposed for 
ways to create such an environment, including using trophic factors, cellular transplants, 
polymeric scaffolds, and combinations of these treatments. These different approaches 
are reviewed in the following sections. 
 
2.3 Neural Tissue Engineering 
 
2.3.1 Design of a neural “bridge” 
Regeneration in the central nervous system has been something of an enigma in 
the scientific community. Since the early 1900s when Ramon y Cajal showed that in the 
presence of certain neurotrophic factors axons could regenerate, the challenge has been to 
provide a design that could deliver the correct amount of these trophic factors to the 
central nervous system post injury to achieve a cure for spinal cord injury.  The goal, 
however, has proven much more difficult than expected. Delivering drugs to the CNS is 
almost impossible due to the natural barriers present, and direct injection, in many cases, 
has proven to be toxic because of the bolous of drug floods the injury site. The simple 
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addition of these trophic factors to a spinal cord injury has also not shown much promise, 
therefore the inclusion of some kind of “bridge”, either cellular or acellular is the current 
design promising to “bridge the gap” in the injured spinal cord11.  Although many bridges 
have been attempted, few have seen ingrowth of axons, and none have seen this bridge be 
crossed. Many researchers now believe the trouble is these “bridges” are such friendly 
environments for the regenerating axons that they have no motivation to leave. 
 
2.3.2   A note on biomaterials and biocompatibility 
 Tissue engineering focuses on designing biomaterials, which are simply any natural 
or synthetic material that can be implanted into the body and function in close intimate 
contact with living cells or tissue. This material might replace tissue, bone, blood vessels 
or even an organ. The first and primary requirement of any biomaterial is that is be 
biocompatible. The classic definition of biocompatible, as given by Buddy Ratner in his 
textbook Biomaterials Science: An Introduction to Materials in Medicine, 
biocompatibility is “the ability of a material to perform with an appropriate host response 
in a specific application.” 12   
 Much emphasis has been placed on the host response to the implanted device, 
including cytotoxicity, immune response and fibrous encapsulation of the implant.  Once 
a material has been tested for a certain application and provides positive results for 
biocompatibility, it cannot be claimed universally biocompatible. The host tissue 
response will vary greatly depending upon the different are area of the body and therefore 
no one material can be deemed biocompatible or not biocompatible universally. Careful 
testing should always be executed to evaluate the biocompatibility of a material in each 
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new design. 
 
2.3.3 Host tissue response to engineered implants 
The classic host tissue response to a biomaterial implant is the same as to any 
foreign body, the inflammatory response12.  The inflammatory response is divided into 
two phases, the acute and chronic phases. The acute phase is where neurtophils and 
excess fluid floods the area. The neurtophils attempt to phagocytize any bacteria or debris 
in the area. When the neutrophils come in contact with the implant, chemical signals 
allow the neurtophil to recognize it as a foreign material. The nuertrophil then attempts to 
engulf (phagocytize) the implant, however the size disparity prevents this from occurring. 
Since the implant cannot be phagocytized, the neutrophil may begin frustrated 
phagocytosis, which leads to the dumping of its contents into the extra cellular matrix12. 
The inflammatory response can either stop here, as an acute response, or continue as a 
chronic inflammatory response if a constant chemical or physical irritation is present12. 
This often occurs when there is a moving tissue-implant boundary, such as in 
biodegradable or free moving implants12.  
Following the inflammatory response, the body responds to the foreign material by 
encapsulating it in a protective layer, in attempt to seal it off from the local tissue. This 
layer is created by macrophages, fibrous tissue, and granulation tissue all of which 
impede cellular and chemical transport to and from the implant12. This level of host 
response can greatly affect the efficacy of the biomaterial to complete its desired 
function. 
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2.3.4 Spinal tissue response to biomaterial and cellular implants 
In the spinal cord, along with a classic foreign body response to an implant, there is 
already an inflammatory response to the injury as well as an upregulation of growth 
inhibitory molecules and the formation of a glial scar4. The glial scar is a combination of 
cell debris, myelin, astrocytes, oligodendrocytes and microglia. The scar formation is a 
major physical barrier to the reconnection of neural processes (mainly axons) with their 
targets4. The goal of a biomaterial implant within the spinal tissue then must be to not 
only elicte minimal inflammatory response, but also to reduce or at minimal not increase 
the formation of the glial scar. The presence of fluid cysts after the macrophage invasion 
of the injury site is also an impedence to bio13-15chemical signal pathways in the spine4, 
so materials implanted into the spine should not create more cysts than already found 
after an injury, rather should aim to prevent the formation of any cysts.  
  
2.4 Delivery of therapeutic proteins as a potential repair strategy 
 
2.4.1 Neurotophic factors that may aide in regeneration: BDNF and 
NT-3  
Brain derived neurotrophic factor (BDNF) and neurotrophin 3 (NT 3) are 
neurotrophic factors (NTF) that promote survival, maintenance and limited regeneration 
of injured neurons in the mammalian CNS. BDNF enhances sprouting near the injury site 
and axon regeneration for variable distances. Transplantation of BDNF-expressing 
fibroblasts into the injured spinal cord promotes axon growth and leads to recovery of 
function16-20. Similarly, NT-3 delivery to the injured spinal cord promotes axon growth 
and plasticity 21-24. The mode of delivery and the inability to deliver multiple NTF 
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simultaneously have been identified as major issues in this field that need to be 
addressed31. Delivery of NTF via osmotic minipumps or ex-vivo gene therapy has been 
suggested to result in excessive sprouting and local growth potentially leading to 
abnormal connectivity and sensory and motor dysfunction.  These results indicated that a 
controlled, sustainable delivery of the trophic factors is necessary. 
 
2.4.2 Drug Delivery in the Central Nervous System  
 Disorders affecting the CNS are the worlds leading cause of hospitalizations and 
disability25. The leading cause of failure in potential CNS drug therapies is not the drug 
itself, rather the delivery system. Research has shown the more localized the delivery of 
the neurotrophic factors the more increased the efficacy and subsequently decreased 
toxicity25, therefore simple injections that flood the CNS are not an optimal approach. 
Several significant barriers exist that make delivery to the CNS extremely difficult. The 
most formidable barrier is the blood-brain-barrier (BBB). The BBB is a membranous 
barrier that separates the brain from the blood acting as a highly efficient screen to lipid 
insoluble (polar) molecules25. Another highly selective barrier to prevent blood borne 
molecules from entering the brain parenchyma is the blood-cerebrospinal fluid barrier 
(BCB). 
 Since the BBB is so highly efficient, drug delivery methods have focused on not 
only optimizing influx into the CNS but also decreasing the efflux back out of the CNS 
(which is also a significant barrier to delivery methods) by creating a sort of “lock-in” 
mechanism25. The optimal properties for uptake into the CNS are lipid solubility, little 
hydrogen bonding, and small sizes 25. However, since the majority of drugs to treat CNS 
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disorders, esp. SCI, are large hydrophobic polar molecules such as NTFs. Proposed 
delivery methods range from modifying the drug to surgical implants.  
 Methods for modifying the drug to increase lipophilicity are often highly drug 
specific and require specific knowledge of the chemistry of the drug. Methods include 
using lipophilic analogs that convert to activated form after crossing the BBB, prodrugs 
that convert to active form via activation step after crossing the BBB, or the use of 
vectors to carry the drug across the BBB and then be cleaved off leaving only the active 
drug25. The obvious difficulties in these methods are the complicated chemistry as well as 
the risk of toxic effects by releasing too much drug at once using the liposome.   Surgical 
approaches have included cathedors/pumps implanted into the spinal cord at the base of 
the neck to release drug into the cerebrospinal fluid 25. Drawbacks to the surgical method 
are again the dumping of too much drug into the spinal cord as well as the obvious 
disruption from the surgery and risk of harming neurons in the process of implanting the 
device. Other methods include using osmotic or biochemical methods to disrupt the BBB 
and BCB 25. Simply put, this method is a little extreme, as it would require treatment with 
incredibly strong antibiotics to avoid the risk of infection (often leading to seizures).  
While the drug can enter the CNS, so could many other unwanted molecules/toxins. 
 
2.4.3 Biodegradable microparticles for drug delivery 
Controlled release is a key design goal of any drug delivery device for increased 
patient compliance, increased efficacy and decreased unwanted side effects from repeated 
uncontrolled dosages. An idealistic release curve for controlled release is shown in figure 
2.4 as compared to the release seen by repeated dosages necessary when IV injections are 
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used. In some cases the IV injections can lead to overdosing of the drug, which leads to 
unwanted side effects, and long-term complications26. The hassle and pain of IV 
injections leads to decreased patient compliance, hence the desire to create a delivery 
device that would only require one injection or dosage26.  
Incorporation of proteins in biodegradable polymeric microparticles is beneficial 
for multiple reasons. Polymeric microparticles protect the protein from proteolysis and 
denatruation (loss of three dimensional structure and therefore function) as well as 
enhance the therapeutic efficacy and can prolong the release of the protein 27. The release 
rate of the protein from these polymeric microparticles has been found to be related to the 
protein loading and polymer degradation rate and proportional to the size of the 
microparticle 28. This allows microparticles to be designed to in such a way that a 
controlled, sustained release of drug can be achieved.   
 
2.4.3.1 Poly-lactic acid as biodegradable material 
In order to be biodegradable, the polymers must gradually degrade over time into 
materials that can be metabolized or excreted from the body. These biodegradable 
particles release their drug via some combination of erosion and diffusion.  Erosion is the 
physical dissolution of the polymer resulting from degradation and is most commonly 
seen as hydrolysis. As the water penetrates the polymer it hydrolyzes the polymer (bulk 
erosion) but if the polymer is highly hydrophobic it must degrade from the surface only 
(surface erosion). In most real systems, the polymerization is a combination of these two 
and an initial burst is seen where surface erosion dominates before bulk erosion can 
occur. Another method for release of the drug is diffusion controlled by the concentration 
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gradient of the drug in the microparticle. This diffusion process in combination with bulk 
erosion and surface erosion is commonly seen in biodegradable devices 29, 30. 
Polymers widely used in these applications include poly (lactic acid) (PLA), poly 
(glycolic acid) (PGA) and their copolymer poly(lactic-co-glycolic acid) (PLGA) 28, 31-35 
whose structures can be seen in figure 2.5. It has been shown that microparticles made 
from PLA with diameters of 300µm or less have approximately a homogeneous 
degradation rate throughout the entire particle 32. The biocompatibility of PLA is evident 
in its frequent use in drug delivery, and it shows only a mild inflammatory response when 
PLA microparticles are injected into tissue 32. The PLA microparticles when injected into 
tissue alone can lead to fibrous encapsulation of the entire microparticle area. 
Incorporation of these microparticles into a non-degradable polymeric hydrogel could 
protect from this cellular response. The incorporation of the microparticles within the 
hydrogel could also serve to localize the delivery minimizing unwanted side effects. 
 
2.4.3.2 Double emulsion particles 
 The double emulsion technique is outlined in Figure 2.6.  The basic process 
involves the dissolving of the chosen polymer into an solvent (known as the oil phase). 
The therapeutic protein, or drug, is then dissolved into an aqueous phase then emulsified 
with the oil phase. This mixture is similar to an oil and vinegar salad dressing; the more 
mixing present, the smaller the water phase beads are in the oil phase. If the agiatation is 
removed, the mixture will eventually settle again into two separate continuous phases. 
The input of energy in the double emulsion method is usually done by sonication or 
through a homoginizer. In order to physically entrap these water phase beads with the 
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polymer, the emulsion is quickly added to a second, larger water phase. The emulsion 
creates a shell of polymer/oil phase around the inner aqueous phase beads. This double 
emulsion, however, is just as unstable as the primary emulsion and requires mixing 
(either homoginizer or magnetic stir bar) to maintain it.  The secondary water phase also 
usually includes a surfactant of some kind to stabilize the emulsion. The oil phase solvent 
slowly evaporates leaving a hardened polymer shell around the water phase drug.  
This method is obviously only valid for drugs that are hydrophilic, and stable in 
aqueous environments.  The double emulsion solvent extraction fabrication is not very 
robust, meaning that any changes in the processing can lead to a different output, 
including changes in the release profile, particle morphology, and encapsulation 
efficiency. However, these multiple process variables make the system tunable to 
different drug-polymer combinations.   Double emulsion particles have been used to 
entrap many different protein therapeutics such as, insulin, albumin, human growth 
hormone, basic fibroblast growth factor (reviewed in Cleland 199736, Soppimath et al 
200137 and Putney 199838, Brannon-Peppas 199539). 
 
2.4.3.3 Protein stability during encapsulation 
 In order to evaluate protein stability during encapsulation, the term stability first 
needs to  be defined. The first level of protein stability is the chemical stability, or simply 
the retention of the primary structure of the amino acid sequence.  However, activity of 
these proteins depends upon retaining their three dimensional structure, which is created 
by the secondary and sometimes tertiary and quaternary structures of these amino acid 
chains40.  Physical stability or biochemical stability of the protein requires that it retain its 
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three dimensional structure as well as the primary amino acid sequence.  This level of 
stability can be assessed by basic biological assays for antibody recognitions (ELISA, 
Western blotting) and size and shape (Circular dichroism, SDS PAGE). Loss of the three 
dimensional structure of a protein is commonly referred to as denaturing of the protein. 
The unfolding, or denaturing, of the protein can easily occur in the presence of high or 
low temperatures, exposure to organic solvents, and changes in pH. The denaturing can 
sometimes be reversed, while aggregation and precipitation of the protein is not so easily 
reversed, and can be caused by similar conditions40. 
 The final level of protein stability is the assessment of biological activity. The 
only way to determine the biological activity is to test if the pharmaceutical efficacy of 
the protein remains functional40. In many applications this test is not so easy to 
accomplish, so biochemical or physical stability is assessed. It should be remembered, 
though, that the physical stability of the protein, while a necessary condition for 
biological activity, does not guarantee biological activity.  
 Several stages in the processing of microparticles can lead to the loss of function 
or physical instability of a peptide or protein based therapeutic. These include the 
exposure of the protein to organic solvents at the phase boundary of both the primary and 
secondary emulsions, as well as mechanical shearing from the sonication or 
homogenization40.  It has been shown that the primary loss of protein stability takes place 
via aggregation at the interface of the primary w/o emulsion boundary.  The protein 
usually unfolds as its hydrophobic core is drawn to the organic side of the interface41.  As 
it turns out, the choice of the solvent itself is critical in maintaining the stability of the 
protein.  
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 In an attempt to aide the protein stability during encapsulation, a few researchers 
have looked into adding different stabilizers to the primary aqueous phase. The most 
common, and effective stabilizer used is serum albumins (either human or  bovine)42-44.It 
is believed that the serum albumins act as a sacrifice protein at the interfaces, by 
preferentially aggregating themselves at the interface instead of the entrapped protein 
therapeutic45. 
 
2.4.3.4 Different solvents for emulsion particles 
One of the most limiting to the design for protein therapeutics is the use of 
hazardous organic solvents for the oil phase. These solvent, especially at the phase 
boundary of the primary aqueous –oil emulsion, can denature the therapeutic protein by 
damaging their secondary and tertiary structures, leaving them inactive41, 46.  The choice 
of solvent, however, is not so simple. The solvent must have a low miscibility with water 
but also be a good solvent for the polymer chosen. If the solvent is at all miscible with 
water, protein can easily be lost to this mixing, especially during the hardening step in the 
secondary water phase, which in most cases is last several hours. The solvent also must 
be readily evaporated, or extracted from the microparticles, since any trace amounts of 
these volatile organic compounds would not be acceptable for clinical applications. 
Birnbaum et al performed a thorough study of the affect of using either ethyl 
acetate, dichloromethane, or a dichloromethane-methanol mixture on the formulation and 
release of ß-estradiol from PLGA microparticles47. It was concluded that the 
microparticles made from ethyl acetate had the most homogenious distribution of ß-
estradiol, and the release from these and the mixture of dichloromethane-methanol was 
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more optimal than from the microparticles fabricated using dichloromethane alone47. 
Studies by other research groups have confirmed that when proteins are encapsulated in 
W/O/W particles with ethyl acetate as the solvent, there is more stabile protein remaining 
than with dichloromethane 36, 46.   
 
2.4.3.5 Encapsulation efficiency  
Another common problem with double emulsion particles is optimizing the 
encapsulation efficiency. Estimating the encapsulation efficiency, how much of the 
attempted drug load makes it into the microparticles, itself is a difficult task. Many 
researchers use the basic principle that the microparticle can be dissolved into a solvent, 
and the drug can then be extracted into water by simple mixing. However, since the 
timescale is not always the same for these methods, it is uncertain how fast the 
equilibrium of these phases is reached. It is also unclear if there is any partitioning effect 
of the drug between the solvent and the water phase. Despite the complications with the 
extraction method, the measurement of the extracted water phase’s concentration of drug 
appears to be the standard method for determination of encapsulation efficiency40. Other 
indirect methods based upon measurement of the loss of drug to the secondary water 
phase have also been attempted. These methods, however, might be underestimating the 
amount of protein lost, since they are only accounting for loss in the final step of the 
process.   
Because of these varied measurement methods, encapsulation has been estimated 
as a wide variety of numbers, usually dependent directly upon processing factors36. In 
most cases there is a large loss of drug, which when using therapeutic proteins and tropic 
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factors, can be a highly expensive loss. Many researchers have focused on methods to 
increase the encapsulation efficiency of the water in oil in water (W/O/W) emulsion 
method by removing one of the water phases to prevent loss of the hydrophilic drug 
across the gradient created between the small concentrated internal phase and the large 
empty external phase.  These methods have included solid emulsions in oil-in-water48, 49, 
solid –in –oil-in oil emulsions, as well as spray drying33, 50, 51.  The results of using solid 
emulsions of proteins within organic solvents have found that the biochemical/physical 
stability of the protein is greater than when dissolved at the interface of the water-oil 
phase boundary52. 
Another method proposed to reduce the effect of the concentration gradient 
created is to saturated the secondary water phase with the drug, this driving the gradient 
in the direction of the particle53. However, when dealing with expensive proteins, 
saturating the secondary phase is often impractical and therefore not recommended. Other 
factors that have been shown to affect the encapsulation in PLA/PLGA based 
microparticles are the concentration of the polymer in the organic phase, as well as the 
concentration of the protein in the aqueous phase, however, these results vary depending 
upon each polymer-drug interaction39, 54-57. 
 Other methods for increased protein stability and encapsulation have proposed the 
use of PLA-PEG blends. The idea is that the inclusion of a hydrophilic block on the 
polymer will help to retain the protein as well as stabilize the emulsion during 
solidification.  Previous research has shown great success at entrapping model proteins58 
59and enzymes 60 within PLA-PEG particles.  
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2.4.3.6  Sterilization of microparticles 
 A major drawback to the use of biodegradable microparticles for delivery of 
therapeutic proteins is the difficulty in sterilizing the polymer. Since the microparticles 
are meant to biodegrade in the presence of an aqueous solution, washing the particles 
with ethanol:water mixtures is not advisable, since it may lead to loss of some of the 
entrapped drug over the washing time. The common sterilization techniques of electron 
beam and steam (autoclave) application are likely to melt the polymer as well as denature 
the protein entrapped from the high temperatures it would be exposed to.   
 A novel solution that has been evaluated by several researchers is the use of 
supercritical fluids for the sterilization and processing of the microparticles. Processing of 
microparticles using supercritical fluids, most commonly supercritical CO2, has been 
successfully done using several techniques (reviewed in Yeo and Kirian 2005 and 
Tomasko et al,2003)61, 62.  A common technique used is known as the rapid expansion 
method, where the polymer and drug are codissolved in the supercritical fluid. The 
supercritical fluid is then rapidly expanded allowing the transition into a tri-phase region 
where the polymer and drug are no longer in solution, and form micron or submicron 
sized composite particles63, 64. The idea that the supercritical fluid itself could sterilize the 
polymer was first identified by Dillow et al.65 
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2.5 Polymeric Scaffolds  
 
2.5.1 Hydrogels  
A hydrogel is a three dimensional network of polymer that can swell in the 
presence of water but does not degrade. It can have either physical cross-links 
(entanglements) or chemical cross-links (actual chemical bonds created by a chemical 
crosslinking agent) (figure 2.7) . Hydrogels can also be referred to as sponges or scaffolds 
interchangeably. Hydrogels make desirable tissue engineering scaffolds because of their 
flexible, highly porous structures that allow high water contents. In many cases, the high 
water contents and large interconnected pore structures have allowed for the ingrowth 
and attachement of different cells which is highly advantageous in tissue engineering 
applications12, 66-71. 
 
2.5.2 PHEMA (A traditional polymeric hydrogel) 
As suggested previously, in order to obtain sustained regeneration of injured 
axons at the site of the spinal cord lesion a scaffold providing support for the growing 
axons and vascular tissue is necessary. It is believed that biocompatible polymer 
hydrogels can reduce scar tissue formation as well as bridge the injured area of the spinal 
cord if surgical implanted into the injury site 72. Such a scaffold must be made of a 
biocompatible material that is nondegradable and provides interconnected pore structures 
greater than 8-10 µm in diameter. This pore structure allows for the ingrowth of vascular 
tissue 73while the nonbiodegradable polymer provides permanent mechanical support for 
the injured site in the spinal cord. A polymer that meets these criteria is poly (2-
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hydroxyethyl methacracylate) (pHEMA) (structure shown in figure 2.8). PHEMA has 
been used in many biomedical applications including the design of soft contact lenses74, 
proving it is a biocompatible material. Studies have also been done where pHEMA 
sponges were implanted in rodents for up to five months resulting in vascular tissue 
surrounding the implants and no toxic side effects 73, 75. 
 Studies into the polymerization of pHEMA have shown that when polymerized 
with excess water as the solvent (concentrations exceeding 40% water) the hydrogel 
formed is phase separated from the water, opaque and heterogeneous 76. These hydrogels 
have increased porosity compared to the homogenous ones formed with less than 40% 
water present. The heterogeneous sponges have highly adaptable pore sizes depending 
upon the conditions during polymerization 76. Optimization of these pore sizes as well as 
the compressive modulus can allow for the hydrogel to match the natural tissue of the 
spinal cord.  
 Polymerizing the HEMA with small amounts of poly(ethylene glycol) (PEG) 
allows for increased porosity as well as stabilizing the scaffold 73. It is believed that the 
PEG acts as a surfactant that allows for the more stable pore structure and helps to attract 
more vascular cells into the implant73.  
 
2.5.3 PNIPAAm-PEG (An injectable polymeric scaffold) 
In the past several years, temperature sensitive and in situ-forming hydrogel 
systems have gained extensive interest for biomedical and pharmaceutical applications.  
One such polymer is poly (N-isopropyl acrylamide) or PNIPAAm, whose structure can 
be seen in figure 2.9. PNIPAAm-based systems have been one of the most commonly 
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proposed thermosensitive materials, not only because its phase transition conveniently 
occurs between ambient and body temperature, but because copolymers of NIPAAm with 
different types of monomers can result in materials with a range of different properties 77. 
The incorporation of hydrophilic comonomers tends to increase the swelling capacity of 
PNIPAAm networks78-79 which allows them to become more macroporous in order to 
incorporate cellular growth. Cho et al. encapsulated human mesenchymal stem cells in a 
PNIPAAm matrix grafted with chitosan.  The cell-thermosensitive gel complex was 
injected into the submucosal layer of the bladder of a rabbit, resulting in cartilage 
growth80. This study shows that PNIPAAm gels are not only biocompatible, but also 
good substrates for cellular growth and attachment. PNIPAAm-based hydrogels can also 
be used to immobilize drugs, enzymes, antibodies, and other biomolecules. An initial 
burst release of surface drug, or other biologically active agent, can occur followed by 
drug release from within the matrix via a diffusion 81. The most desirable properties of 
PNIPAAm based hydrogels is that they are in situ-forming hydrogels that do not require 
cross-linking in vivo eliminating the risk of excess reactants. There in situ-forming ability 
also allows them to mold to the injection site. 
 
2.5.4 Hydrogels with incorporated microparticles  
 Although intense studies have been performed on both hydrogels and 
microparticles as drug delivery devices little work has been done to evaluate the 
combination of both into one design.  Using the knowledge of controlled release achieved 
from microparticles and combining these microparticles into a localized delivery for 
tissue engineering in a hydrogel scaffold can create a potentially long-term implantable 
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device capable of stimulating regeneration for prolonged periods of time.  Preliminary 
studies have been done to asses the ability to incorporate microparticles within a hydrogel 
matrix, but little to no work has been to done to evaluate what is the effect on the 
hydrogel morphology or mechanical properties.  
 
2.6  Hydrogel designs for neural tissue engineering 
Many investigators have focused on using scaffolds to create a bridge across the 
site of SCI11, 82. These previously attempted scaffolds can be divided into three major 
groups: acellular, cellular, and combinations of both. Most acellular scaffolds have been 
designed using polymeric hydrogels consisting of a biodegradable polymer, which 
requires pre-molding and an invasive surgery for implantation.  Some representative 
findings, for these designs are summarized in table below. (OES= olfactory enseathing 
cells, SC = Schwann cells, ESC= emybronic stem cells, NPC= neural precursor cells, 
MSC= marrow stromal cells)  
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Despite the somewhat promising results seen in all these designs, where some 
axon growth in the scaffold was seen, very minimal functional recovery is ever present. 
The polymeric scaffold alone is always the minimal approach, and inclusion of trophic 
factors, cells, guidance channels, or a combination of the three is necessary for significant 
axonal recovery to be seen. 
 
 
Biomaterial Cells Injectable Guidance 
channels 
References # 
PHEMA-PEG    Bakshi et al (2004)83 
PHEMA-
EDMA 
ESC   Horak et al (2004)84 
PHEMA-co-
MMA 
 
 
 yes Piotrowicz and Shoichet (2006)85, 
Dalton et al (2002)86, Flynn et al 
(2003)87 
PHEMA/ 
PHPMA 
(NeuroGel™) 
SC   Lensy et al (2002)72, Woerly et al 
(2001, 1996, 1993)18-20  
80/20 PLA/PCL hNGF-EcR-
293-TK Cells 
  Dhar et al (2006)21 
PLA   yes Patist et al (2004)22 
PLA-PEG-PLA  yes  Burdick et al (2006), Levenberg et al 
(2006), Park et al (2007), Piantino et al 
(2006), Teng et al (2002)23-27 Maquet, 
et al (2001)28 
Polycarbonate SC  yes Harvey et al (1995)29 
Fibrin gels    Ju (2007)30 Taylor et al, (2004)31 
Alginate SC, OES   Novikova et al (2006)32Kataoka et al 
(2001)33 Suzuki et al (1999, 2002) 34 
Matrigel 
(laminin based) 
SC, OES  yes Novikova et al (2006)32 Xiao et al 
(2005)35Iannotti et al (2003) 36 
Collagen MSC  Yes Harley et al (2004)37, 38Klapka & 
Muller(2006)39 Yoshii et al (2004)40 
Collagen –type I 
Vitrogen™ 
 NPCs   Lepore et al (2005)41 
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2.6.1 PHEMA based scaffolds for neural tissue engineering 
A widely studied polymer for non-biodegradable designs is poly (2-hydroxyethyl 
methacrylate) (PHEMA. These materials are desirable because they can create three 
dimensional hydrogel structures that retain high water contents, and can be formulated to 
match the mechanical properties of the native tissue12, 14, 17-20.  As with many previously 
attempted polymer scaffolds, PHEMA on its own is not sufficient for growing axons to 
maneuver through the bridge. Attempts at soaking the gel with BDNF or the inclusion of 
guidance channels have shown increases in axon growth but not functional recovery12, 14. 
A similar polymer design, poly (N-2-(hydroxypropyl) methacrylamide) 
(Nuerogel™) has a similar three dimensional hydrogel structure to PHEMA. It has been 
shown that with the addition of the cell-adhesive sequence Arg-Gly-Asp (RGD) post 
implantation into a transected rat spinal cord, blood vessels, glial cells and Schwann cells 
were all able to penetrate the Nuerogel™19. In this study, however, minimal functional 
recovery was observed.  
 
2.6.2 Scaffold design elements 
 In an attempt to improve upon the basic polymeric bridges proposed earlier, many 
different design elements have been investigated. These include, but are not limited to, 
the use of degradable polymers, guidance channels, injectable polymers, and mechanical 
optimization of the polymeric hydrogel. Some key findings for each of these designs 
elements are discussed in the following sections. 
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2.6.2.1 Degradable vs. non degradable 
Common degradable materials for scaffold designs are either poly(lactic acid) 
PLA,  PLA based copolymers, fibrin or collagen. All these materials degrade over time 
and can be can be designed with copolymerization with different polymer blocks to 
adjust their degradation rates. These designs provide only temporary mechanical support 
to the injury site and do not guarantee injured axons a stable surface for regeneration. If 
the degrading scaffold looses its stabilization ability before the axons sufficiently 
regenerated, the injury site will be subject to compressive stresses again leading to more 
cell death and inflammation12. If the scaffolds are designed to increase cellular 
attachment and biocompatibility, then the removal of such an attractive environment for 
the regeneration tissue could be detrimental. As the scaffold degrades it creates a moving 
boundary layer between the tissue and biomaterial that can lead to an increased 
inflammatory response and glial scar formation.  
 
2.6.2.2 Guidance channels 
 A common design element to overcome this challenge is the inclusion of 
guidance channels 15, 42. Guidance channels, essentially long tubes, are designed to guide 
growing axons through the scaffold, a picture of the idealized guidance channels can be 
seen in Figure 2.10.  Tsai et al have seen that the inclusion of channels into a PHEMA 
based scaffold did promote in-growth of axons, and if the channels were filled with a 
degradable component such as collagen, or fibrin, axon regeneration increased38.  
Despite the impressive results of axon growth into the channels, no research yet 
has seen significant functional recovery. Another key design flaw with the guidance 
 29 
channels it the surgical implantation of these channels may be difficult due to their rigid 
structure and the inability to align the channels exactly with growing axons.  
 
2.6.2.3 Injectable scaffold designs  
A few innovative researchers have begun to look into injectable scaffolds, which 
would allow a space-filling mode that would also allow for a minimally invasive surgical 
technique. These scaffolds also have the desirable property of molding to the irregular 
shaped injury site. However, most of these scaffolds require gelation (crosslinking) in 
vivo which could lead to complications from unreacted monomer or excess reactants26.  
 
2.6.2.4 Mechanical mismatch of the scaffold 
Many polymeric scaffolds do not address yet another key design parameter – 
mechanical mismatch. If matrices are not correctly engineered, it can lead to implant 
failure15. Ozawa et al, have done some impressive mechanical analysis of the white and 
gray matter of the spinal cord tissue. These studies have found that the compressive 
modulus of the spinal cord white matter is on the order of 3-5kPa 43, 44. These studies 
provide a baseline order of magnitude that should be used in all mechanical analysis of 
neural tissue engineered constructs. 
 
 
 
 30 
2.7  Cellular approaches 
Previously attempted cellular scaffolds have included Schwann cells, olfactory 
ensheathing cells, fibroblasts, marrow stromal cells, and neural precursor cells42, 45-50. 
Using cellular scaffolds is of great interest because a small number of cells could 
potentially fill a large “gap”. Transplanted cells provide not only matrices for growing 
axons, but they may also provide the necessary trophic factors and extracellular cues 
necessary for axonal regeneration. Cellular scaffolds, although biologically 
advantageous, do not meet a lot of the biomechanical requirements. Cells do not 
necessarily remain contained within the injury site, nor do they provide sufficient 
mechanical stabilization. Since cellular bridges lack the full design requirements, many 
researchers have focused on acellular, polymeric bridges or combinations of both. The 
combination scaffolds provide the mechanical stabilization, a substrate for cellular 
growth, as well as the trophic factors and stimulation necessary for axon regeneration; 
however, many of the approaches still suffer the same problems as the acellular 
polymeric scaffolds, namely the difficulties in transplanting rigid structures, the limited 
cell motility within the scaffold and the material mismatch.  
Advances in stem cell biology have raised hope that grafts with the potential to 
differentiate into all major cell types of the spinal cord will be able to replace neurons and 
glial cells destroyed or rendered dysfunctional by injury and will ultimately form relays 
or provide bridges through the injury site. There has been considerable progress in 
isolating and characterizing neural stem cells and precursors from different regions of the 
CNS 51. These cells have substantial advantages over fetal tissue grafts that have been 
used previously for cellular replacement. Large numbers of well-characterized cells can 
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be isolated and expanded from multiple sources, stored in quality-controlled cell banks 
and approved for clinical applications.  
 
2.7.1 Marrow stromal cells as potentially therapeutic transplants 
 Marrow stromal cells (MSCs, also known as mesenchymal stem cells) are easily 
accessible compared to most other proposed transplanted cell lines, and are found largely 
in the bone marrow.  Transplanted MSC in injured mice models show they are capable of 
migrating to the injured tissue52. Transplanted MSCs have also shown the ability to 
attract host cells to the transplantation site53. It is believed that greatest benefit of using 
these transplanted cells is the ability to express and secret different cytokines and growth 
factors54. The transplantation of these cells into injured rat spinal cords yielded locomotor 
improvements as measured on the BBB scale, and can be attributed to the release of 
growth promoting factors from the MSCs 54.  
 
2.7.2 Neural precursor cells as potentially therapeutic transplants 
The properties of multipotent neural stem cells and lineage-restricted neural 
precursor cells (NPC) derived from the spinal cord of fetal alkaline phosphatase (AP) 
transgenic rats have been studied extensively41, 55-58. NPCs grafted into the intact adult 
spinal cord differentiated into mature glia and mature neurons, which integrated with the 
host spinal cord55, 56.  Also, NPC grafted into the adult injured spinal cord survived well 
and differentiated into mature neural cell types41. Graft-derived neurons exhibited limited 
axon growth into the host59 but were capable of forming structural synapses with the 
host60. In contrast to the robust survival and differentiation of lineage-restricted NPC 
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grafts into both neurons and glia, transplants of multipotent neural stem cells exhibited 
poor survival in brain and spinal cord suggesting that the non-neurogenic adult CNS is 
more amenable to survival of precursors than uncommitted multipotent cells58. Also, 
multipotent neural stem cells preferentially differentiated into glial cells rather than 
neurons in the non-neurogenic adult spinal cord 61. It is likely that lineage-restricted NPC 
provide a microenvironment that protects developing neurons at the injury site and 
presents developmental cues for their differentiation. Indeed, mixed NPC have been 
shown to support recovery of function following a contusion injury suggesting that these 
precursors are ideal for grafting into the injured CNS62. 
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Figure 2.1 Neuron structure.  
Neurons, the specialized cells of the nervous system, have a large cell body and long 
process extensions known as axons and dendrites. Axons tend to be much longer than the 
branched, tree like structure of the dendrites. Signals are received by dendrites, passed 
down to the cell body and then sent to the next neuron via the axon. 
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Figure 2.2 The spinal cord.   
The central nervous system is composed of the brain and the spinal cord. The spinal cord 
is divided into two major tissue sections, the gray matter (butterfly shaped area that 
consists mainly of cell bodies) and the white matter (largely axons for cell signal 
transduction). It is covered by a protective layer of tissue, the outermost layer known as 
the dura matter. 
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Figure 2.3 Spinal cord injury morphology. 
 This picture shows the formation of a fluid cyst after the initial spinal cord injury and the 
presence of the glial scar, both of which prevent the injured axons from reconnecting to 
their targets. (Image from Wings for Life organization website). 
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Figure 2.4 Controlled release versus repeated dosages. 
 The above graph shows the  idealized controlled release of a drug versus repeated 
dosages as a function of blood plasma levels over time. The therapeutic window is 
marked as the upper and lower limits of drug concentrations that provide a beneficial 
effect. Levels above this window can lead to unwanted side effects and below do not 
have any therapeutic effect. 
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Figure 2.5 PLA and PGA chemical structures.  
(A) PLA : poly (lactic acid), (B) PLGA (poly lactide co glycolide). These two polyesters 
are some of the most common biomaterials used in biodegradable microparticle designs.  
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Figure 2.6 Double emulsion solvent evaporation method of microparticle formation. 
The most common method of microparticle formulation is to use a water in oil in water  
double emulsion, solvent evaporation. In this method, the drug is dissolved in the primary 
aqueous phase, and the polymer is dissolved in an organic solvent (oil phase). This 
primary emulsion is then mixed and immediately added to a second emulsion (second 
water phase), where the solvent can be evaporated or extracted while the particles harden 
prior to collection. 
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Figure 2.7 Hydrogel structures. 
  Hydrogels are simply water swollen three dimensional polymer structures that are either 
chemically crosslinked (A) or physically crosslinked (B){Lowman, 2004 #47}.   
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Figure 2.8 Chemical structure of PHEMA: poly (2-hydroxy ethyl methacrylate). 
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Figure 2.9 Chemical structure of PNIPAAm. Poly(N-isopropyl acyrlamide) 
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Figure 2.10 Guidance channels for neural tissue engineering.  
A common design element in neural tissue engineering scaffolds is to include guidance 
channels for axon growth. The idea is that these channels, sometimes referred to as 
conduits, can be aligned to direct the growth of the injured axons to their targets. These 
can be either hallow tubes created through a polymeric scaffold (A) or bundles of tubes 
that could later enseathed in a degradable coating after implantation (B). 
Guidance channels 
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Chapter 3  Delivery of therapeutic proteins with 
biodegradable microparticles 
 
 
 
 
3.1 Introduction 
 Incorporation of proteins in biodegradable polymeric microparticles is beneficial 
for multiple reasons. Polymeric microparticles protect the protein from proteolysis and 
denatruation (loss of three dimensional structure and function) as well as enhance the 
therapeutic efficacy and can prolong the release of the protein 1. The release rate of the 
protein from these polymeric microparticles has been found to be related to the protein 
loading and polymer degradation rate and proportional to the size of the microparticle 1. 
 In order to minimize the toxic side effects of NTF proteins introduced to an injured 
region of the spinal cord, the release should be sustained at low levels. Biodegradeable 
and biocompatible polymeric microparticles can be designed to give the desired release 
of NTF. Polymers widely used in these applications include poly(lactic acid) (PLA), poly 
(glycolic acid) (PGA) and their copolymer poly(lactic-co-glycolic acid) (PLGA) 2-7. 
In order to obtain the desired release of the drug for the specific delivery, increasing the 
amount of glycolic acid can increase the degradation rate, and therefore speed the release 
time. However, for this application, prolonged release is the goal, so only PLA was used 
in testing. 
 Many researchers have studied the ability of altering release profiles of 
microparticles for inorganic compounds as well as some proteins and peptides, but few 
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have investigated their ability to maintain protein stability through the processing and 
release. Proteins are easily denatured molecules, which makes processing using 
traditional polymer chemistry methods impossible.  Protein and peptide drugs are also 
usually considerably more expensive than their inorganic counterparts. The high cost of 
the drugs puts great emphasis on decreasing the waste in processing. Most microparticle 
designs using double emulsion methods have low encapulation efficiencies, therefore 
wasting a large amount of protein in processing alone. Methods that have increased the 
drug loading previously have focused on over-saturating the primary aqueous phases, or 
secondary aqueous phases. These methods would require an extreme waste of money and 
drug in the case of therapeutic protein drugs, and therefore new methods should be 
developed to make this application more realizable.  
 Despite their great potential, microparticle designs have rarely made it from the 
biochemical laboratory even into animal studies. The barrier to this field moving forward 
is the inability to sterilize these degradable microparticles. Obvious sterilization 
techniques that are used in other biomaterial applications, such as steam, ethylene oxide, 
ethanol washes or electron beam exposure would not work for the microparticles since 
they would not only degrade the polymer they could potentially denature the entrapped 
protein therapeutic. It has been proposed by other researchers8 that exposure to 
supercritical CO2 could be used to sterilize the polymer during the processing steps of the 
microparticles.  It is then believed that a similar technique could be used post processing 
to sterilize the dried microparticles.  
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The focus of these studies was as follows: 
1. Optimize the encapsulation efficiency of a model protein in poly(lactic acid) double 
 emulsion microparticles. 
2. Verify the size, shape and morphology of the microparticles fabricated using the 
double emulsion techniques. 
3.  Ensure the biochemical stability of the protein throughout processing. 
4.  Test the release profiles from the double emulsion microparticles. 
5.  Test the ability of supercritical CO2 to sterilize the microparticles without degrading 
or melting the PLA. 
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3.2 Experimental Section 
3.2.1 Materials 
 Poly (lactic acid) (PLA, 100 IV, high DL) was purchased from Lakeshore 
Biomaterials (Birmingham, AL).  Poly (ethylene glycol) disterate, bovine serum albumin, 
citric acid, 3,3'',5,5'' – Tetramethylbenzidine (TMB), carbonate-bicarbonate capsules for 
enzyme linked immunosrobent assays (ELISA) Dulbecco’s phosphate buffered saline 
10x powder, tween 20, acetone, ethyl acetate and dichloromethane were purchased from 
Sigma Aldrich (St. Louis, MO). Equine albumin was purchased as a lyophilized powder 
from Rockland Immunochemicals (Gilberstville, PA). Human serum albumin was 
purchased from SeraCare (Gaithersburg, MD) as a lyophilized powder.  Sheep 
monoclonal anti-albumin was purchased from Bethyl Labs (Montgomery, TX) as was 
monoclonal HRP conjugated sheep anti-albumin.  Sulfuric acid and Tris-HCl were 
purchased from Fisher Scientific. The BCA protein assay and the FITC-ez-label protein 
kit were purchased from Pierce Biotechnology and used per manufacturers instructions. 
Poly vinyl alcohol (88 mol% hydrolyzed) was purchased from Polysciences (Warrington, 
PA). All solvents purchased were of reagent grade.  
 
3.2.2 Microparticle synthesis 
 Microparticle synthesis was done using two variations of double emulsions-solvent 
evaporation methods. The first was the classic water in oil in water (W/O/W) method and 
the second is the more novel approach of the solid in oil in water (S/O/W) method. 
Equine albumin was used as a model protein for characterization and release studies 
because of its low cost and inexpensive detection assays. 
 56 
 
3.2.2.1 Water in oil in water emulsion 
The water in oil in water method is a common emulsion technique that relies of 
the phase separation of oil and water. Briefly, 150µL of citrate buffer (0.15 M citric acid 
in PBS, pH 7.6) with varying amounts of dissolved protein was added to 2mL of the oil 
phase (10mg/mL PLA in ethyl acetate) and the emulsion was created by adding energy to 
the solution by placing it in a bath sonicator for 60 seconds. The primary emulsion was 
stabilized with the addition of human serum albumin (1mg/mL) to the internal aqueous 
phase. The primary emulsion was then quickly added to 400mL of an external aqueous 
phase (5wt% PVA, 5v/v% isopropyl alcohol (IPA)). The emulsion was stabilized through 
stirring at 400RPM and the presence of the PVA.  The microparticles hardened while 
stirring overnight and the ethyl alcohol was evaporated/extracted via the IPA. The 
microparticles were collected via centrifugation at 10,000RPM for 30 minutes and 
washed with deionized water prior to lyophilizing. Lyophilized particles containing drug 
were used immediately or kept at 40C until use.  
 
3.2.2.2 Solid in oil in water emulsion 
A second method of encapsulation was evaluated using a solid in oil in water 
method. This method is similar to the previous method with the exception being the 
protein was added as solid crystals into the oil phase formed the first emulsion. The same 
process was used for the second emulsion, hardening, washing and collecting as was 
done in the W/O/W microparticle fabrication.  
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3.2.3 Microparticle Morphology 
 Scanning electron microscopy samples were lyophilized and a monolayer of 
microparticles was coated with platinum using a Spin coater G3-P8 prior to viewing on a 
FEI XL30 Environmental SEM, at 10 kV, spot size 3, and 1.4x10-4kPa.  Confocal 
microscopy was done with the aide of Drs. Brian Hawkins and Tom Dziubla, at the 
University of Pennsylvania on their Leica TCS SL and DMRE microscope.  
 
3.2.4 Encapsulation efficiency 
Particle encapsulation was evaluated by dissolving a known weight of particles 
(5mg) in 2mL DCM. The dissolved particles were mixed with 2mL of deionized water 
and the solvent-water mixture was shaken overnight at 200RPM. This provided sufficient 
time for the protein to be extracted into the water phase. A sample was taken from the 
water phase and the concentration was found using a BCA protein assay (used per 
manufacturer’s instructions).  The BCA protein assay is a colorimetric assay based on 
bicinchoninic acid and measures the total protein content in a sample. Since samples also 
contained small amounts of human serum albumin as a stabilizer, blank particles without 
drug loaded were taken as a background reading to find the level of human serum 
albumin present, which could then be subtracted from the sample readings. Negative 
controls of the particle made with no protein present at all were also performed to ensure 
that the presence of the degraded lactic acid did not affect the concentration readings. 
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3.2.5 Protein stability 
Maintaining protein stability during processing is of great importance in this 
design and was evaluated using circular dichroisim spectroscopy (CD), western blotting 
as well as sandwich ELISA.  
 
3.2.5.1 Western Blotting 
 Aliquots of release medium were taken and kept at 40C prior to analysis. PAGE 
samples were prepared by mixing 20µL of release medium with 5µL of LDS sample 
buffer with BME (Invitrogen). Samples were loaded into a 1.5 mm thick 15 well SDS-
poly acrylamide gel (NuPage 4-12% bis-tris, Invitrogen). A molecular weight ladder was 
run for control and 25µL of each sample was loaded into the gel.  The gel was exposed to 
a constant current (200mV) for 50 minutes while immersed in 1x MES-SDS Running 
Buffer (Invitrogen) at room temperature. The protein was then transferred to a PVDF 
membrane (soaked in methanol for 30 seconds, and washed with distilled H20) at 
constant current (0.135 amps) for 3 hours. The western was then blocked (50mL PBST + 
2.5g milk, Invitrogen) overnight at 40C. The western was then washed 5 times for 15 
minutes in PBST, followed by blotting with monoclonal sheep-anti-albumin (1:1000, 
Bethyl Labs) for one hour at room temperature. The sample was then washed and blotted 
with the secondary detection antibody (HRP conjugated anti-sheep, 1:5000, Invitrogen) 
for one hour. The protein bands were visualized by enhanced chemiluminescence 
(Amersham, Piscataway, NJ) with the aide of Dr. Aleister Saunders, Drexel University, 
Department of Bioscience and Biotechnology. 
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3.2.5.2 Sandwich ELISA 
 Enzyme linked immunosorbent assays (ELISA) were done for equine albumin 
using a kit purchased from Bethyl Labs (Montgomery, TX). Briefly, tissue culture grade 
uncoated 96-well polystyrene plates were coated for 1 hour with sheep monoclonal anti-
equine albumin (1:1000) in coating buffer (0.5 M carbonate-bicarbonate, pH 9.6).  The 
plate was then washed four times with wash solution (50mM Tris, 0.14M NaCl, 0.05% 
Tween 20, pH 8.0), followed by blocking with bovine serum albumin (50mM Tris, 
0.14M NaCl, 1%BSA, pH 8.0) for 30 minutes.  The plate was again washed four times 
prior to incubation with 100µL of each sample and standard for 2 hours.  The plate was 
washed four times again and incubated for 1 hour with the secondary antibody (HRP 
conjugated sheep anti equine albumin, Bethyl Labs, 1:25,000). The plates were washed 
and the HRP conjugate was reacted with tetramethyl benziodine (TMB solution, SIGMA) 
for 5-20 minutes (until color appeared). The reaction was stopped with 2M H2SO4 and 
the plate was immediately read on a Biotek microplate reader (ELx800UV) at 450 nm.  
Known equine albumin standards were run on every plate. Optical density readings were 
converted to concentrations using a calibration curve fit to equine albumin standards 
(Bethyl Labs). 
  
3.2.5.3 Circular dichroism spectroscopy 
 Bovine albumin was dissolved in citrate buffer (1mg/mL) and mixed with 
increasing volumetric ratios of solvent (dichloromethane or ethyl acetate) and placed in a 
quartz cuvette with an optical path length of 1 cm. The spectrum was measured from 270 
to 190 nm at 250C using an Aviv Model 215 Circular Dichroism Spectrometer using 2 
nm steps and a 5-sec integration time.  Samples were also run at increasing temperature 
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(250C to 850C) under similar conditions. 
 
3.2.6 Release studies 
Protein release from the microparticles was evaluated in vitro using USP standard 
dissolution cells (Distek Waterbath dissolution, model # 2100C). Dissolution cells (200 
mL) were used with paddle impellers. Known masses of dried microparticles were added 
to a known volume of phosphate buffer solution (SIGMA, pH 7.6, 370C).  All studies 
were set so sink conditions would be maintained, specifically, that at no point would the 
maximum released concentration of protein be greater than 10% the saturation limit for 
that protein in PBS. Sample of the release medium were removed at designated times 
using a sample probe with an inline 0.45µm filter to prevent removal of microparticles 
during sampling. Equal volumes of fresh PBS was back-flushed through the filter to 
ensure a constant volume throughout the study as well as to ensure any microparticles 
trapped in the sample probe would be flushed back into the dissolution cell.  Samples 
were kept at 40C until analysis.  Concentrations were found using a sandwich ELISA 
specific for the model protein used as well as with the BCA protein assay for verification 
of the ELISA results. Calculated concentrations were adjusted based on the amount of 
release medium replaced after each sample was taken. 
 
3.2.7 Sterilization  
 Microparticles were sterilized post-processing using exposure to supercritical 
carbon dioxide. Briefly, the dried microparticles were exposed to supercritical CO2 at 
varying temperatures (00C or 250C) and lengths of exposure (15 minutes, 45 minutes, 
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1hr), and under either 500 or 1500 psi of pressure with the aide of Dr. Randy Weinstein, 
at Villanova University. The particles were removed from the chamber under sterile 
conditions and kept sterile from that point forward. 
 
 62 
3.3 Results 
3.3.1 Encapsulation efficiency of double emulsion microparticles 
 The encapsulation efficiency of the double emulsion method, i.e. the effectiveness 
of loading drug into the particles, is another key design parameter. The encapsulation 
efficiency was found by dissolving a known mass of lyophilized microparticles in DCM 
to dissolve the polymer shell. The addition of water allows the hydrophilic drug to be 
extracted into the water phase that could then be analyzed using either an enzyme-linked- 
immunosorbent assay (ELISA) or a BCA protein assay. These assays are both indirect 
measurements that calibrate to known protein standards.  
 The resulting total protein loaded was converted into encapsulation efficiency by 
dividing the amount loaded by the amount attempted to be loaded.  Figure 3.1 
summarizes the results found for varying solvent to polymer ratio’s and attempted protein 
loading for both DCM and ethyl acetate methods.  In all cases, ethyl acetate had lower 
encapsulation efficiency. Attempting to increase the loading did not improve efficiency 
and increasing the amount of polymer relative to solvent also did not improve the 
loading.  
 A different emulsion method and a polymer blend were then investigated as 
alternative strategies to increase the encapsulation. These included the S/O/W method 
and a 50:50 blend of PLA and PEG-distearate and can be seen in figure 3.2.  The best 
encapsulation efficiency (85.1% +/- 3.4%) was found using W/O/W with DCM as the 
solvent.   
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3.3.2 Microparticle characterization 
 The size, shape and morphology of the microparticles were examined using 
electron scanning microscopy (SEM). A monolayer of the dried particles was coated with 
platinum and viewed for their size distribution, surface morphology, and to ensure a 
round morphology. The results for the different emulsion methods (W/O/W, S/O/W (both 
PLA) and PLA-PEG W/O/W) can be seen in Figure 3.3. In order to provide a proof of 
principle that the microparticles were comprised of polymer on the outside and protein 
inside as believed, FITC-labeled bovine albumin was entrapped into PLA microparticles 
using the W/O/W method. The microparticles were then exposed to a hydrophobic red 
dye (Nile Red, Sigma), and then wet mounted, cover slipped and viewed with a confocal 
microscope. The results, in figure 3.4, clearly show that the protein (green) is contained 
within the polymer shell (red). In some cases, as indicated by the arrow in the figure, 
several water phase droplets were entrapped within a single microparticle.  
Microparticle size was also tested using a HORIBA particle size analyzer, however, since 
the size of the microparticles seen under SEM did not correlate with the results the 
HORIBA was providing, and had large variability these results were not taken as accurate 
and this method was no longer used. 
 
3.3.3 Biochemical stability of the protein throughout processing 
 Viability of the protein during encapsulation was evaluated by assessing the effect 
of solvent exposure and temperature on secondary structure using CD spectroscopy. The 
native structure of albumin is alpha helical and the presence of a peak at 222nm is 
characteristic for alpha helices. The loss of this peak represents the loss of the native 
structure of the protein. The results for the thermal stability are seen in Figure 3.5. 
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Increasing the temperature of the aqueous protein solution decreases the presence of the 
native structure. In figure 3.6, part (A) shows the addition of DCM quickly leads to a loss 
of native tertiary structure, while part (B) shows that ethyl acetate at the same working 
conditions retains the alpha helical peak at 222nm. 
 
3.3.4 Release profiles from the double emulsion microparticles 
 Release from the microparticle formulations using the ethyl acetate in both W/O/W 
and S/O/W formulations were tested in vitro in dissolution cells. Microparticles made for 
release via W/O/W or S/O/W were used immediately after lyophilizing for 48hrs. 
Microparticles for release were made with PLA (5mg/mL) in ethyl acetate and equine or 
bovine albumin (5 wt%).  25 mg of dried microparticles were added to 30 mL of PBS and 
stirred at 100 RPM. 0.5 mL samples were taken at 1.5, 5, 10, 15, 30, 60, 90 minutes, 2, 4, 
24, 48 hours, 3, 4, 7, 14 days. Equal volumes of fresh buffer were replaced to maintain 
the solution volume at every timepoint. Samples were analyzed using an equine albumin 
specific ELISA, the BCA protein assay and western blot analysis. The BCA protein assay 
was used to verify results found from the ELISA.  The western blot was used to evaluate 
the size and antibody recognition of the samples released. The western blot (Figure 3.7 
A) results show that the released protein is recognized by the antibody and that it is the 
protein was not degraded.  The ELISA results are summarized in Figure 3.7B.  
 The burst release is defined as the immediate release of proteins from the 
microparticle upon immersion in release media. The burst from both the S/O/W and the 
W/O/W are minimal, 4% and 3% respectively. The release then changes to a slow linear 
profile over the next 14 days for both formulations. The total amount release in the two 
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weeks was only 8% of the total protein encapsulated, indicating that the release could 
then predictably last for several months.  
 
3.3.5 Sterilization of PLA microparticles using supercritical CO2 
 In order to assess the sterility of the microparticles following exposure to 
supercritical CO2, they were placed into a tissue culture dish with 5mL of fresh sterile 
PBS and kept in the incubator (5% CO2, 370C) for up to four days. The dish was checked 
every 24 hours for the presence of bacteria. All exposures tested were found to be sterile 
within the 96 hours tested.  
Viewing the microparticles with SEM following CO2 exposure showed that in all 
cases, the microparticle structure was lost. Representative SEM images are seen in the 
SEM images in figure 3.8. In most cases the polymer melted, and in some cases the 
polymer is believed to have dissolved in the supercritical CO2 because none could be 
retrieved from the chamber following exposure. These results are summarized in table 3.1 
for the different exposure conditions tested.  
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Figure 11 Microparticle encapsulation efficiency 
The encapsulation efficiency of microparticles using different variations of protein 
loading, polymer content and solvent type were calculated and found that in all cases 
DCM had higher encapsulation efficiencies. (A dichloromethane, B ethyl acetate) 
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Figure 12 Encapsulation efficiency of albumin using different encapsulation 
methods.   
Albumin encapsulation efficiency in double emulsion microparticles using soild in oil in 
water and water in oil in water emulsion techniques showed that the W/O/W with DCM 
as the solvent has the highest encapsulation efficiency (~85%). 
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Figure 13 Microparticle morphology.  
SEM images of the microparticles fabricated using (A) W/O/W with DCM, (B) W/O/W 
with ethyl acetate (sb=50µm)  and (C) S/O/W show that the particles are spherical in all 
cases (sb=200µm).  
 
 69 
      
 
A                                                B 
 
Figure 14 Confocal microscopy images of microparticles synthesized using the 
W/O/W method.  
In part A the FITC-albumin can be seen while in part B the PLA is stained with a red 
hydrophobic dye (Nile Red). The images together show that the protein is encapsulated 
inside the polymer (scale bar is 10 microns). 
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Figure 15 Thermal stability of albumin.  
Using CD spectroscopy the presence of a peak at 222nm shows the presence of alpha 
helical structures (the native tertiary structure found in albumin protein); therefore the 
disappearance of this peak with increasing temperature represents the denaturation of 
albumin. 
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Figure 16 Solvent affects on the native structure of albumin. Using CD spectroscopy 
the presence of a peak at 222nm shows the presence of an alpha helical structure, 
therefore the disappearance of this peak with increasing solvent represents the 
denautation of the protein. Part (A) shows addition of DCM while part (B) shows the 
addition of ethyl acetate to albumin, where the native structure in both is the protein at 
1mg/mL in citrate buffer. 
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Figure 17Albumin release from PLA microparticles.  
(A) Shows the release samples from W/O/W particles with DCM as the solvent stained 
using a western blot. The blot shows that the protein released is antibody recognized and 
of the correct size. (B) The graph shows the difference in protein released from W/O/W 
particles versus S/O/W particles. Both formulations have a minimal burst (3-4%) and 
then a slow release for the 14 days sampled. The S/O/W particles have a larger burst 
leading to a higher final % release after 14 days. 
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Figure 18 PLA microparticles post sterilization. 
 PLA microparticles were sterilized by exposing them to supercritical CO2 in a 
pressurized chamber post fabrication. The particles were exposed to different pressures, 
temperatures, as well as varying lengths of exposure time. In all cases, the polymer was 
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melted, and the microparticle morphology was lost. A (500psi, 1hr, 250C. sb=20um), B 
(1500psi, 1hr, 00C, sb=200um), C (1500psi, 15 min, 250C, sb=1um) 
 
 
 
 
 
Exposure time 
(min)
Pressure 
(psi)
Temperature 
(C) 
Result
60 500 25 melted
60 500 0 dissolved
60 1500 25 none recovered
60 1500 0 melted
15 1500 25 melted
15 1500 0 dissolved  
 
Table 3.1 Results from different CO2 exposure conditions.  
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3.4 Discussion 
3.4.1 Microparticle fabrication 
 Protein stability testing throughout the fabrication process showed that the most 
optimal solvent for the double emulsion process was ethyl acetate because it was the least 
damaging to the secondary structure of the protein. However, ethyl acetate showed a 
significant decrease in the encapsulation of the model protein as compared to the more 
traditional solvent (DCM). The loss of encapsulation efficiency in W/O/W with ethyl 
acetate when compared to DCM is due to the miscibility of the solvents in water. The 
ethyl acetate is slightly miscible with water, therefore the particles were not stabilized 
within the secondary aqueous phase during hardening and protein was likely lost from the 
particles. In order to increase the encapsulation efficiency of the microparticles, while 
still using the more desirable solvent, a S/O/W double emulsion method was the best 
option. The higher encapsulation efficiency in these formulations was also expected 
because the W/O/W emulsions lose most of the protein during their hardening step when 
concentration gradients drive the protein from the interior aqueous phase to the larger 
exterior aqueous phase.  Changing the solvent and double emulsion technique did not 
greatly affect the size distribution, shape or morphology of the resulting microparticles. 
 
3.4.2 Release profiles 
 The release from S/O/W encapsulated microparticles had only a marginally higher 
burst release than W/O/W formulations. The higher burst is likely a result of more protein 
being at the surface of the S/O/W microparticle formulations. Any protein stuck to the 
outer surfaces, or near the surface during fabrication would be release immediately as 
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part of the burst effect. However, since a detailed distribution of the protein throughout 
the microparticle was not tested in either method, it is difficult to assess for certain if 
there is a difference in surface concentrations. The most promising result of the initial 
release is minimal burst exhibited in both cases, since burst release is a common 
drawback to microparticle formulations. 
  Both formulations showed an ideal linear controlled release for up to 14 days after 
the initial burst, and would likely continue to do so for several weeks.  
 
3.4.3 Sterilization 
 Although the CO2 exposure following fabrication of the microparticles was able to 
give a sterile polymer, in all cases the spherical morphology was destroyed.  However, it 
is still believed that further optimization of the sterilization process could allow for 
supercritical CO2 exposure to provide an efficient sterilization technique for 
microparticles. If the sterilization were to take place either prior to fabrication, melting of 
the polymer would not matter since it would be later dissolved into fabrication, which 
could be maintained in a sterile environment. Another option would be to include the 
sterilization with supercritical CO2 as part of the processing technique, by simply 
dissolving the polymer in the supercritical CO2 instead of a solvent and using this as part 
of the emulsion process.  
 
3.5 Conclusions 
  The primary goal of this work was to design a biodegradable microparticle 
fabrication method in which, biochemically stable therapeutic proteins could be 
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encapsulated at high efficiencies and released over extended periods of time (several 
weeks) with minimal burst. Different adaptations of the double emulsions solvent 
evaporation/extraction method were attempted in order to increase the encapsulation 
efficiency, leading to the highest efficiency of nearly 85%; however, this was using a 
non-optimal solvent (dichloromethane, DCM). DCM was found to be extremely 
hazardous the biochemical/physical stability of the model proteins tested, while ethyl 
acetate, was much more forgiving. Therefore, ethyl acetate is proposed to be the best 
solvent for the purposes of encapsulating stable albumin using a double emulsion 
method. The classic W/O/W method did not yield sufficient encapsulation efficiencies 
and it was found that changing to a S/O/W method gave improved encapsulation results.  
 The release from the S/O/W microparticles exhibited a minimal burst with an 
extended linear release of the protein for two weeks. The trend seen in the W/O/W 
microparticles was the same as the S/O/W particles, so it is believed the same release 
mechanism (a combination of surface degradation and bulk erosion) controlled the 
release in both types of microparticles. The S/O/W microparticles were therefore 
considered the best option for encapsulation of therapeutic proteins and peptides when 
using PLA as the biodegradable polymer.  
 The sterilization of the microparticles using supercritical CO2 post processing is a 
novel concept, that has proven to effectively sterilize the polymer, however, further 
investigation into protein stability and optimal conditions for preservation of 
microparticle morphology should be further investigated. 
 78 
 
3.6 References 
1. Brannon-Peppas, L., Recent advances on the use of biodegradable microparticles 
and nanoparticles in controlled drug delivery. International Journal of Pharmaceutics 
1995, 116, (1), 1-9. 
2. Cao, X., M.S. Shoichet, Biodegradation and biocompatibility of PLA and PLGA 
microspheres. Biomaterials 1998, 20, 329-339. 
3. D.T., S. S. O. H., A comparison of alternative methods for the determination of 
the levels of proteins entrapped in poly(lactide-co-glycolide) microparticles. 
International Journal of Pharmaceutics 1995, 115, (2), 259-263. 
4. Panyam J, D. M., Sahoo SK, Ma W, Chakravarthi SS, Amidon GL, Levy RJ, 
Labhasetwar V., Polymer degradation and in vitro release of a model protein from 
poly(D,L-lactide-co-glycolide) nano- and microparticles. 
. J Control Release 2003, 92, (1-2), 173-187. 
5. Shive, M. S.; Anderson, J. M., Biodegradation and biocompatibility of PLA and 
PLGA microspheres. Adv Drug Deliv Rev 1997, 28, (1), 5-24. 
6. Uchida T, Y. K., Ninomiya A, Goto S., Optimization of preparative conditions for 
polylactide (PLA) microspheres containing ovalbumin. Chem Pharm Bull (Tokyo) 1995, 
43, (9), 1569-73. 
7. Witschi, C., E Doekler, Influence of the microencapsulation method and peptide 
loading on the poly (lactic acid) and poly (lactic co glycolic acid) degradation during in 
vitro testing. J Control Release 1998, 51, 327-341. 
8. Dillow, A. K., Fariba Dehghani, Jeffery S Hrkach, Neil R Foster, Robert Langer, 
Bacterial Inactivation by using near- and supercrical carbon dioxide. Proc Natl Acad Sci 
U S A 1999, 96, (18), 10344-10348. 
 
 
 79 
Chapter 4 Evaluation of different polymeric scaffolds for 
tissue engineering applications 
 
 
 
 
 
4.1 Introduction 
 
Tissue engineering is a rapidly expanding field that aims to regenerate or replace 
damaged tissues with synthetic scaffolds. Of great interest in this field is the application 
of synthetic scaffolds that enhanced ex vivo for their biocompatibility and promotion of 
new cellular growth prior to implantation. A common design for these synthetic scaffolds 
is to use polymeric hydrogels. 
 Hydrogels are simply water-swollen polymer networks held together either by 
physical entanglements or chemical crosslinks. This swelling ability of the polymeric 
scaffolds allows for a relatively high fraction of free water to be entrapped in the scaffold, 
therefore matching the high water contents of natural tissue. The large water content in 
the hydrogels often leads to a macroporous structure with pore diameters on the micron 
scale. This large pore diameter, along with interconnectivity of these pores, allows for the 
desired result of. However, since hydrogels have such large water content, and usually a 
large pore structure, they do not serve as effective long-term drug delivery vehicles. This 
is a problem in most tissue engineering applications, since delivery of therapeutics 
proteins is necessary for the proliferation of transplanted cells and regeneration of the 
native tissue.   
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 Microparticles are a heavily studied vehicle for delivery of proteins and peptides 
for controlled release applications. Microparticles serve as an excellent choice for protein 
delivery because their polymeric shell protects the protein from changes in pH, enzymes 
and even clearance via the kidneys by increasing their size above 40kDa.  Through the 
selection of the biodegradable polymer, drug release profiles from microparticles can be 
tailored to the desired application.  The draw back to microparticles for tissue engineering 
is the retention of the particles within the targeted tissue. Microparticles can be injected 
through an IV or Sc injection, however, once in systemic circulation, the challenge is 
targeting the desired tissue and retaining the microparticles there.   
 An innovative design for attracting microparticles to their target sites includes a 
ligand for target specific receptors on the surface of the microparticle. Taking advantage 
of this specific cellular signaling mechanism, while ingenuous, is not always possible in 
tissue engineering applications, where signal pathways have not yet been elucidated.  We 
propose that combining these two strategies could be an effective method for tissue 
regeneration. The hydrogel could still serve as a scaffold for the tissue regeneration, 
while also acting as a physical entrapping device for the microparticles to target and 
retain them within the desired tissue.   
 In this chapter three different scaffolds are evaluated; both a traditional 
implantable hydrogel design, based on poly (2-hydroxy-ethyl-methacrylate) (PHEMA) as 
well an injectable design based on the thermo responsive polymer, poly (N-
isopropylacrylamide) (PNIPAAm). 
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The main goals of this chapter are as follows: 
1.  For all three scaffolds: 
a. Is the scaffold macroporous? 
b. Can microparticles be successfully added to the scaffold? 
c. What does the addition of microparticles do to the mechanical properties of the  
scaffold? 
d. Can the scaffold be made soft enough for neural tissue engineering? 
e. Does the addition of microparticles affect the swelling properties of the 
scaffold?  
2. Do microparticles affect the phase transition properties of PNIPAAm-PEG 
copolymer? 
3.  Which scaffold is best suited for neural tissue engineering? 
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4.2 Experimental section 
 
4.2.1 Materials 
 
Poly (lactic acid) (PLA, 100DL, High IV, specific viscosity 0.8) was purchased 
from Lakeshore Biomaterials. 2-hydroxy ethyl methacrylate (HEMA) was purchased 
from Sigma Aldrich and contained small amounts of inhibitor that was removed by 
passing the monomer through a DEHIBIT column (Polysciences, Warrington, PA). Once 
un-inhibited, monomers were stored at 40C for no more than three months.  N-
isopropylacrylamide (NIPAAm) was purchased from ACROS Chemicals and was 
purified by washing the monomer with hot hexane (50oC). Polyethylene glycol di 
methacrylate (200)(PEGDM) and poly ethylene glycol mono methacrylate 
(200)(PEGMA), polyethylene glycol diol (PEG, Mn~ 8000), and poly vinylalcohol 
(PVA, 88% mol hydrolyzed) were purchased from Polysciences (Warrington, PA).  
Redox initiators, sodium metabisulfite and ammonium persulfate were purchased from 
Sigma Aldrich, as well as the thermal initiator, aziobisisobutylnitrile (AIBN). Elvenol 
(high MW PVA, Mw~95,000) was purchased from DuPont Inc. (Wilmington, DE).  
Methacryloyl chloride was purchased from Alfa Aesar and glycidyl methacrylate was 
purchased from Sigma Aldrich.  
 
4.2.2 Blank microparticle preparation 
  Microparticles were prepared using a double-emulsion solvent extraction method. 
In all studies, for this chapter, microparticles were made from PLA with no protein 
loaded inside, and referred to as simply “blank” microparticles. Briefly, 150µL of citrate 
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buffer was added to with 2mL of the oil phase (PLA at 10mg/mL dissolved in ethyl 
acetate) and the emulsion was created by adding energy to the solution by placing it in a 
bath sonicator for 60 seconds. The primary emulsion was then quickly added to 400mL 
of an external aqueous phase (5wt% PVA 5v/v% isopropyl alcohol). The emulsion was 
stabilized through controlled stirring at 400RPM and the presence of the PVA.  The 
microparticles hardened while stirring overnight and the ethyl alcohol was 
evaporated/extracted via the IPA. The microparticles were collected via centrifugation at 
10,000RPM for 30 minutes and washed with deionized water prior to lyophilizing. 
 
 
 
 
4.2.3 Scaffold Synthesis 
 Three different polymeric hydrogel scaffolds were synthesized and evaluated for 
swelling, mechanical and morphological changes with the addition of blank PLA 
microparticles. 
 
4.2.3.1 PHEMA –PEG 
The polymeric scaffold was made by polymerizing HEMA using redox initiation at 370C, 
under N2 atmosphere for 12 hours.  The redox imitators used were sodium metabisulfite 
and ammonium persulfate at 1wt% each. The PHEMA was simultaneously crosslinked 
with the PEGDM (200) to form a solid hydrogel with branches of PEGMA (200) to 
increase porosity1. Scaffolds were synthesized at varying v/v% solvent to reactants during 
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polymerization to tailor their mechanical properties. The reactant mixture was made 
using the following ratio of HEMA: PEGMA: PEGDM (33:5.3:1) based upon previous 
studies by Dziubla et al1.  PLA microparticles were included in the scaffold via the 
solvent phase during polymerization in order to physical entrap them within the 
chemically-crosslinked structure. Microparticles were re-suspended in a 50:50 mixture of 
deionized water and glycerol. Glycerol acted as a surfactant to prevent settling of the 
microparticles during polymerization. Microparticles were added at 5, 10, and 20 (weight 
per volume solution)%.  Samples were washed with deionized water prior to analysis to 
remove any excess reactants. 
 
 
 
4.2.3.2 PHEMA-PVA  
 Methacrylated PVA was made using at 10wt% solution of Elvanol (PVA 
Mw~90,000, DuPont, Inc., Wilmington, DE).  Glycidyl methacrylate was added drop 
wise (7mL total) too 100mL of PVA solution alternating with hydrochloric acid to attain 
a solution pH of 1.5. The mixture was stirred overnight and the methacrylated PVA was 
precipitated in cold ether. The PVA-MA was then dried, ground and dissolved in dH20 at 
0.5mg/mL for a use.  PHEMA-PVA scaffolds were synthesized in the same manor as 
described as for PHEMA-PEG, however PVA-MA was used as the crosslinker instead of 
PEGDM. The solvent phase for these scaffolds did not contain any glycerol, since PVA 
acted as a surfactant for the resuspended microparticles as well as a crosslinker for the 
PHEMA scaffold. 
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4.2.3.3 PNIPAAm-PEG  
PEGDM (8000) was synthesized by reacting PEG (8000) diol with an excess of 
methacylrylol chloride under anhydrous conditions as described by Bryant et al2.  The 
efficiency of this reaction was assessed using 1H NMR (Varian 300, Palo Alto, CA) and 
comparing the integral area under the peak for the vinyl protons to area of the PEG 
protons3.  The PNIPAAm-PEG copolymer was polymerized as previously described by 
Vernengo, et al3.  Briefly, the NIPAAm monomer was mixed with PEGDM (8000) at a 
700:1 monomer ratio in methanol and the free radical polymerization was thermally 
initiated by azobisisobutylnitrile (AIBN) at 650C. The reaction was allowed to go until 
completion (48hrs) prior to removal of excess methanol through evaporation. The 
copolymer was ground and purified by washing with hexane and dried. 10 wt% aqueous 
polymer solutions were made using diBulco’s phosphate buffered saline (PBS).  The 
molar ratio of the PNIPAAm:PEG was assessed using proton NMR.  
 
4.2.4 Microscopy 
Scanning electron microscopy samples were lyophilized and coated with platinum 
using a Spin coater G3-P8 prior to viewing on a FEI XL30 Environmental SEM, at 10 
kV, spot size 3, and 1.4x10-4kPa.  For confocal microscopy sections of the scaffold 20µm 
thick were cut on a Microm HM 550VP and images were taken using a Leica TCS SP2 
microscope, at the Drexel University College of Medicine.  
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4.2.5 Swelling characteristics 
 PHEMA-PEG and PHEMA-PVA scaffold samples were prepared at desired 
solvent vol % and particle concentration and immersed in ~15mL of dibulco’s phosphate 
buffered saline (PBS) at 37oC. Samples were massed at 2, 4, 7, 14, 21, 28 days in air 
(Mair) and in n-heptane (Mheptane) in order to determine the density (ρ) and volume (V) of 
the scaffolds over time. An initial wet mass in air and heptane prior to immersion in PBS 
was taken for each sample as the initial value (t=0).  The mass and volume retention were 
taken to be the ratio of mass (or volume) at time t to mass (or volume) at time zero.  After 
swelling samples were dried via lyophilizing to view under SEM as well as to obtain their 
dry mass post swelling to evaluate their water content (equations 1). 
! 
%WaterContent =
Mair (t) "DryMass(t)
Mair (t)
#100                                      4.1 
 A similar procedure was used for PNIPAAm-PEG samples, were samples were molded 
in 24 well tissue culture dish at 37oC for one hour. Samples were then removed, massed 
and immersed in ~15mL of PBS at 37oC and at desired time points they were removed as 
previously described. Samples for PNIPAAm-PEG however were not massed more than 
once, so each time point was its own separate sample to prevent any mass loss in 
handling at room temperature.  
 
4.2.6 Mechanical testing 
The compressive moduli of all samples were evaluated after swelling in PBS at 
370C using an Instron mechanical testing system (Model 4100, Series IX software, Park 
Ridge, IL).  Cylindrical scaffold samples were tested in a custom made immersion bath 
 87 
that allowed for samples to be immersion in PBS at 37oC. Samples were compressed at a 
strain rate of 100% per minute and load versus displacement data were collected. The 
load and displacement could be converted to stress versus strain by using the 
premeasured dimensions of each sample. The compressive modulus was taken as the 
slope of the linear region of the stress-strain curve (from 0-15% strain).  
 
4.2.7 Lower critical solution temperature determination 
The lower critical solution temperature (LCST) of the PNIPAAm-PEG solutions 
was found using a Differential Scanning Calorimeter from TA Instruments (Model # 
2010, Wilmington, DE). A 10mg sample was placed in an allodized aluminum pan that 
was hermetically sealed then heated from 10 to 600C at 100C per minute. The onset 
temperature for the endothermic phase transition on the DSC thermograph was taken to 
be the LCST. 
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4.3 Results 
 
 
4.3.1 PHEMA-PEG scaffolds 
4.3.1.1 Is the scaffold macroporous? 
 Through much effort in our laboratory, the most effective way we have found to 
assess the porosity of water-soluble hydrogels is by viewing sections of the scaffold 
either through traditional scanning electron microscopy or environmental scanning 
electron microscopy (where the sample is not dried prior to analysis). Samples of 
PHEMA-PEG scaffolds were lyophilized and sputter coated with platinum prior to 
viewing. The typical results for the porosity of the PHEMA-PEG scaffolds can be seen in 
figure 4.1. 
 
4.3.1.2 Can microparticles be successfully added to the scaffold? 
In order to assess the ability of the scaffold to entrap microparticles, different 
amounts of particles were added (0, 5, 10, 20 wt/vol%) to the reactant mixture prior to 
polymerization. The particles were then physically entrapped within the polymerizing 
matrix.  Since previous results had shown that particles would not easily re-suspend in 
the reactant mixture without agglomerating or sinking to the bottom, a 50-50 mixture of 
glycerol and distilled water was used to re-suspend the particles4. The glycerol then acted 
as a surfactant for the particles keeping them in an evenly disperse emulsion during 
polymerization. The typical results seen for SEM imaging of the entrapment of 
microparticles in the PHEMA scaffolds can be seen in figure 4.2. SEM results show that 
microparticles can be physically entrapped within the polymeric scaffold. 
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 In order to confirm the particles were not only at the surface of the scaffold (as 
seen with the SEM) but disperse through out the scaffold, fluorescent particles loaded in 
a PHEMA scaffold. This scaffold was then sectioned and viewed under confocal 
microscopy. The results are seen in figure 4.3 (a) and a rotated image of the section can 
be seen in 4.3 (b). The confocal results give positive evidence that the microparticles are 
evenly dispersed throughout the polymeric scaffold. 
 
 
4.3.1.3 Can the scaffold be made soft enough for neural tissue 
engineering? 
 Previous researchers have evaluated the compressive moduli of the spinal cord at 
3-5kPa5, 6. The primary goal of these studies then was to design a PHEMA-PEG scaffold 
that emulated the same stiffness as the natural tissue. All scaffolds were tested after seven 
days immersion in PBS, and kept immersed in PBS for the testing.  The compressive 
moduli were taken to as the slope of the linear region (0-15% strain) of the generated 
stress versus strain curve during compressive testing.  
The major variables that affect the polymerization and the stiffness of the scaffold 
are the amount of polymer present (as compared to the volume of solvent), the type of 
crosslinker, the amount of crosslinker and the amount of branching with PEG. Since 
previous work done by Dziubla and Lowman1, 7 has shown what amounts of PEG 
branching create ideal porosity for vascularization, this variable was not changed. During 
the design process, it was noted that the addition of therapeutic proteins in microparticles 
during polymerization could become a problem if temperatures were to rise above 
physiological temperatures (370C), and so thermal initiators used at 650C could not be 
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used in further processing of these scaffolds.  For this reason, redox initiators were 
evaluated for their ability to polymerize PHEMA-PEG at 370C and their resultant effect 
on the mechanical properties of the scaffold.  A comparison of the scaffolds compressive 
moduli after seven days immersion in PBS made at similar conditions with either thermal 
or redox initiators can be seen in table 4.1.  Similar results for the compressive moduli 
after seven days immersion in PBS for scaffolds made from varying ratios of solvent: 
reactants are also shown in table 4.1 (where % is referring to the amount of solvent phase 
present during polymerization). It is clear from these results that the scaffolds that best 
matches the mechanical stiffness of the native spinal cord tissue (3-5kPa) are in the 70-
75% solvent (or 30-25% polymer) range. 
 
4.3.1.4 What does the addition of microparticles do to the mechanical 
properties of the scaffold? 
 Microparticles were added to the scaffold at 5, 10 and 20 wt/vol% and scaffolds 
were immersed in PBS at physiological temperatures (37oC) for 2, 4, 7, 14, 21, and 28 
days prior to mechanical testing. Previous results showed that 70-75% solvent created a 
scaffold soft enough for neural tissue replacement, so these scaffolds were evaluated for 
their mechanical changes with the addition of microparticles. The compressive modulus 
of the scaffold was found as described previously and can be shown over time for varying 
amounts of particles added to the scaffold at 70 % and 75% solvent (figure 4.4). The 
scaffold modulus is not affected as a result of the microparticles over time in either case. 
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4.3.1.5 Does the addition of microparticles affect the swelling properties 
of the scaffold?  
 The swelling properties of the scaffold upon addition of 5, 10, and 20 wt/vol% 
microparticles was evaluated by immersing (n=5) scaffolds in PBS at 370C for 1,2,4, 7, 
14, 21, and 28 days. The scaffolds weight and dry masses were compared in order to 
determine their average mass retention and water content over time. These can be seen 
for both the 70 % and 75% solvent scaffolds in figure 4.5 and figure 4.6 respectively. It is 
clear that the addition of microparticles does not affect the water content or mass 
retention over time of the scaffolds in either case. In both cases the scaffold reaches 
equilibrium quickly, but show a large immediate loss of mass. 
 
 
4.3.2 PHEMA-PVA scaffolds 
4.3.2.1 Is the scaffold macroporous? 
Samples of PHEMA-PVA scaffolds were lyophilized and sputter coated with 
platinum prior to viewing. The typical results for the porosity of the PHEMA-PVA 
scaffolds can be seen in figure 4.7, showing a macroporous scaffold can be achieved. 
 
4.3.2.2 Can microparticles be successfully added to the scaffold? 
In order to assess the ability of the scaffold to entrap microparticles, different 
amounts of particles were added (0, 5, 10, 20 wt/vol%) to the reactant mixture prior to 
polymerization. The particles were then physically entrapped within the polymerizing 
matrix. Unlike the 50-50 mixtures of glycerol and distilled water that was used to 
resuspend the particles for the PHEMA-PEG scaffolds, the PVA attached the PHEMA as 
a crosslinker acted as its own surfactant for the microparticles. The typical results seen 
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for SEM imaging of the entrapment of microparticles in the PHEMA scaffolds can be 
seen in figure 4.8.  This image show evidence of the microparticle entrapment, however, 
the particles, as indicated by the arrows, have degraded significantly since these scaffolds 
were immersed in PBS for 60 days prior to imaging.  
 
4.3.2.3 Can the scaffold be made soft enough for neural tissue 
engineering? 
 All scaffolds were tested after seven days immersion in PBS, and kept immersed 
in PBS for the testing.  The compressive moduli were taken to as the slope of the linear 
region (0-15% strain) of the generated stress versus strain curve during compressive 
testing. The results for the compressive modulus of scaffolds of PHEMA-PVA at vary 
solvent content can be seen in table 4.2. It is clear from these results that 80% solvent, or 
20% polymer, is necessary to obtain a scaffold soft enough for neural tissue replacement.  
 
4.3.2.4 What does the addition of microparticles do to the mechanical 
properties of the scaffold? 
Microparticles were added to the scaffold at 5, 10 and 20 wt/vol% and scaffolds 
were immersed in PBS at physiological temperatures (37oC) for 2, 4, 7, 14, 21, and 28 
days prior to mechanical testing. Since previous results found that the scaffold was 
closest to the native tissue modulus at 75-80% solvent, these were the scaffolds evaluated 
for the affect of particle addition. However, since the PHEMA-PEG scaffolds were tested 
at 70% and 75% solvent, 70% was kept for a direct comparison to PHEMA-PEG. The 
compressive modulus of the scaffold was found as described previously and the results 
for the equilibrium moduli (after 30 days immersion) are shown for increasing 
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microparticle addition in table 4.2. The addition of microparticles did not show a 
statistically significant effect on the compressive modulus of the PHEMA-PVA scaffolds. 
The 80% scaffolds could not be formed beyond 5% microparticle addition.  
 
4.3.2.5 Does the addition of microparticles affect the swelling properties 
of the scaffold? 
The swelling properties of the scaffold upon addition of 5, 10, and 20 wt/vol% 
microparticles was evaluated by immersing (n=5) scaffolds in PBS at 370C for 1,2,4, 7, 
14, 21, and 28 days. The scaffolds wet and dry masses were compared in order to 
determine their average mass retention and water content over time. Again, the 70%, 75% 
and 80% solvent scaffolds were tested and the results can be seen in figures 4.9, 4.10 and 
4.11 respectively. In all solvent: polymer ratios the scaffold water content reached 
equilibrium quickly (1-2 days) and the mass retention is much greater than the PHEMA 
scaffolds. The addition of microparticles has no clear effect on the swelling properties in 
the PHEMA-PVA scaffolds 
  
4.3.3 PNIPAAm-PEG scaffolds 
4.3.2.1 Is the scaffold macroporous? 
Two main variables can be altered in the processing of the PNIPAAm-PEG 
copolymer that can drastically change the mechanical and morphological properties of 
the resulting scaffold. The ratio of the NIPAAm: EG monomers can be varied, and was 
set at a high PEG content (700:1) or a low content (1600:1). These ratios were previously 
studied for other applications in our lab and for consistency were kept as the high and low 
PEG contents3. Another variable that has been assessed is changing the PEG branch 
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length by using a different molecular weight PEG methacrylate. The PEG branch lengths 
tested varied from Mn = 400 to Mn = 8000. In order to determine which molar ratio of 
PNIPAAm:PEG monomers as well as which PEG branch length yielded a macroporous 
hydrogel, samples were viewed with a scanning electron microscope. Samples of 
PNIPAAm-PEG scaffolds were flash frozen in liquid nitrogen to preserve their structure 
prior to lyophilizing. Samples were then sputter coated with platinum prior to viewing.  
The SEM results for the different PEG contents and PEG molecular at 700:1 monomer 
ratio, with a PEG branch length of Mn=8000 in Figure 4.12. 
 
4.3.2.2 Can microparticles be successfully added to the scaffold? 
 Since previous results indicated that the 700:1 monomer ratio PNIPAAm-PEG 
copolymer with a PEG branch of Mn=8000 was sufficiently porous for neural tissue 
engineering applications, this scaffold was tested for its ability to incorporate 
microparticles. The particles were simply added to the viscous aqueous polymer solution 
that served as its own surfactant. The scaffolds were molded and immersed in PBS for 
seven days prior to flash freezing in liquid nitrogen. Scaffolds were then lyophilized, 
sputter coated with platinum and viewed using a scanning electron microscope. The 
results can be seen in Figure 4.13 where the arrow indicates a successfully entrapped 
microparticle, however, the microparticle is again degraded from a combination of 
immersion in PBS and sensitivity to the electron beam used in the SEM. 
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4.3.2.3 Can the scaffold be made soft enough for neural tissue 
engineering? 
 Based on previous research by Vernengo et al, it was determined the softest 
scaffolds were using a high PEG content (700:1 monomer ratio) and a high molecular 
weight PEG branch ( Mn= 8000). However, these scaffolds were still an order of 
magnitude greater than what was desired for neural tissue applications. Since water 
dominates all other effects in hydrogel strength, increasing the water content was 
determined to be the best approach at softening the scaffold. In order to soften the 
scaffold, an aqueous solution at lower polymer concentration (10 wt%) than use by 
Vernengo et al3 (15 wt%) was attempted to asses its resulting compressive modulus after 
seven days immersion in PBS.  Scaffolds formed at 15-wt% copolymer were found to 
have an equilibrium compressive modulus of 52.3 +/- 8.9 kPa3, however, decreasing the 
copolymer content to 10-wt% decreased the scaffold modulus to 2.2 +/- 0.6 kPa. This 
puts the scaffold right in the desired range for neural tissue engineering (3-5kPa)5, 6. 
 
4.3.3.3 Do microparticles affect the phase transition properties of 
PNIPAAm-PEG copolymer? 
 Since the ability of the PNIPAAm-PEG copolymer to exhibit a lower critical 
solution temperature phase change is what makes it so desirable as an injectable scaffold, 
it was critical that the addition of microparticles to the solution not change that phase 
transition. In order to assess the lower critical solution temperature (LCST) was found for 
solutions of copolymer with increasing amounts of microparticles (5, 10, 20 wt/vol%) 
using the onset temperature for the phase change as the LCST.  The results for the LCST 
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analysis, seen in table 4.3, show that as hoped, the addition of microparticles had no 
effect on the LCST of the copolymer. 
 
4.3.2.5 What does the addition of microparticles do to the mechanical 
properties of the scaffold? 
Microparticles were added to the scaffold at 5, 10 and 20-wt/vol% that were 
immersed in PBS at physiological temperatures (37oC) for 7 days prior to mechanical 
testing. Since previous results found that the scaffold was closest to the native tissue 
modulus at 700:1 NIPAAm:EG and PEG branches of Mn=8000, this copolymer was 
evaluated for the affect of particle addition. The compressive modulus of the scaffold was 
found as described previously and can be shown for varying amounts of particles added 
to the scaffold in table 4.3. The addition of microparticles showed a direct correlation 
with increasing scaffold compressive modulus. 
 
4.3.2.6 Does the addition of microparticles affect the swelling properties 
of the scaffold?  
The swelling properties of the scaffold upon addition of 5, 10, and 20 wt/vol% 
microparticles was evaluated by immersing (n=5) scaffolds in PBS at 370C for 1,2,4, 7, 
14, 21, and 28 days. In order to be consistent with results found previously in our lab for 
other variations of the PNIPAAm-PEG copolymer, these time points are slightly different 
than those tested for the PHEMA-PEG and PHEMA-PVA scaffolds. The scaffolds wet 
and dry masses were compared in order to determine their average volume retention and 
mass retention over time and can be seen in figure 4.14.  
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Figure 19 Morphology of the PHEMA-PEG scaffold.  
SEM of a lyophilized PHEMA-PEG scaffold made from 75% solvent shows that this 
polymeric hydrogel exhibits an interconnected macroporous structure.  Results for 70% 
solvent (not pictured) also exhibited a macroporous structure.  
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Figure 20  The morphology of the PHEMA scaffold with microparticles added. 
Microparticles were entrapped in the scaffold by adding them to a suspension of 50:50 
water and glycerol.  This suspension was then used as the solvent for the polymerization. 
The particles then become physically entrapped in the highly porous hydrogel as shown 
in the SEM image (scale bar is 10 microns).  The cracking evident in the microparticle is 
a result of the PLA polymer melting from the electron beam. 
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Figure 21 Confocal microscopy of entrapped microparticles.  
To confirm the entrapment of microparticles throughout the scaffold, fluorescent-labeled 
microparticles were entrapped within a PHEMA-PEG scaffold using a 50:50 mix of 
water-glycerol to suspend the microparticles.  The scaffold was sectioned every in 20 
micron thick sections that were viewed under confocal microscopy. The above images 
are of a section from the center of the scaffold showing that the microparticles are present 
throughout. (Scale bar is 200 µm). 
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Table 2 The compressive results for varying the amount of solvent for two different 
initiators for PHEMA-PEG scaffolds.   
The compressive modulus was found after 7 days immersion in PBS, and taken to be the 
slope of the generated stress versus strain curve over the linear region (0-15% strain). 
Moduli presented are the average of n=5 samples with the standard deviation shown 
(stdev). In all cases, the redox initiators created softer scaffolds. 
Water % Initiator Modulus (kPa) Stdev
50 thermal 500 10
70 thermal 30 1
80 thermal 9 0.5
50 redox 460.12 11.0169
70 redox 73.6 0.6
80 redox 1.43 0.21
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Figure 22 The compressive modulus of PHEMA-PEG scaffolds with microparticles 
incorporated.  
 The compressive moduli of  PHEMA-PEG scaffolds with microparticles were measured 
after immersion in PBS over time. The compressive modulus was taken as the slope of 
the linear region of the stress-strain curve (0-15% strain). Error bars indicate the standard 
deviation for n=5 samples. Part (A) shows the results for scaffolds made from 70% 
solvent, while part (B) shows 75% solvent scaffolds, and in both cases the addition of 
microparticles has no clear effect on the scaffold compressive modulus. 
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Figure 23 The swelling properties of the 70% solvent PHEMA scaffolds. 
 70% solvent PHEMA-PEG scaffolds with increasing (wt/vol)% microparticles were 
immersed in PBS at 370C, where the control has no microparticles. The scaffolds water 
content and mass retention were calculated over time from measurements of wet and dry 
masses. Part (A) shows the water content, while part (B) shows the mass retention. 
Although equilibrium water content is reached quickly (1-2 days), the scaffolds loose a 
large amount of mass in that first day, but remain constant after that. 
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Figure 24 The swelling properties of the 75% solvent PHEMA scaffolds.  
75% solvent PHEMA-PEG scaffolds with increasing (wt/vol)% microparticles were 
immersed in PBS at 370C. The scaffolds water content and mass retention were 
calculated over time from measurements of wet and dry masses. Part (A) shows the water 
content, while part (B) shows the mass retention. Although equilibrium water content is 
reached quickly (1-2 days), the scaffolds loose a large amount of mass in the first day but 
remain constant after that. 
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Figure 25 Morphology of the PHEMA-PVA scaffold.  
ESEM of a wet PHEMA-PVA scaffold made from 75% solvent shows that this 
polymeric hydrogel exhibits a porous structure.  Results for 70% and 80% solvent (not 
pictured) also exhibited a porous structure, none of which where as porous as the 
PHEMA-PEG scaffolds. 
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Figure 26 Morphology of the PHEMA-PVA scaffold with incorporated 
microparticles.  
ESEM of a wet PHEMA-PVA scaffold made from 75% solvent with incorporated 
microparticles after 60 days of swelling shows that this scaffold was able to physically 
incorporate microparticles into the porous hydrogel network as evidence by the wholes 
left in the hydrogel. The particles are hard to view at 60 days since most are degraded (as 
indicated by the arrows).  
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Table 3 The compressive modulus of the PHEMA-PVA scaffolds with 
microparticles incorporated.  
The compressive moduli of  PHEMA-PVA scaffolds with microparticles were measured 
after immersion in PBS over time. The compressive modulus was taken as the slope of 
the linear region of the stress-strain curve (0-15% strain). Error is reported as the standard 
deviation of the n=5 samples measured, and the control in each case has no 
microparticles added. The 80% solvent scaffolds were not able to be formed with 10 and 
20% microparticle addition.  
Compressive 
modulus (kPa)
control 114.3 +/- 12.6
5% 116.4 +/- 9.9
10% 64.5 +/- 2.3
20% 73.3 +/1 13.3
control 42.2 +/- 6.9
5% 41.4 +/- 9.1
10% 38.5 +/- 8.5
20% 46.9 +/- 5.3
control 13.1 +/- 1
5% 3.6 +/- 1
10% N/A
20% N/A
75% 
solvent
80% 
solvent
Sample
70% 
solvent
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Figure 27 The swelling properties of the 70% solvent PHEMA-PVA scaffolds. 
70% solvent PHEMA-PVA scaffolds with increasing (wt/vol)% microparticles were 
immersed in PBS at 370C. The scaffolds water content and mass retention were 
calculated over time from measurements of wet and dry masses. Part (A) shows the water 
content, while part (B) shows the mass retention. Equilibrium water content is reached 
quickly (1-2 days), and in all cases the scaffolds do not loose a large amount of mass like 
the PHEMA-PEG scaffolds. 
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Figure 28 The swelling properties of the 75% solvent PHEMA-PVA scaffolds 
75% solvent PHEMA-PVA scaffolds with increasing (wt/vol)% microparticles were 
immersed in PBS at 370C. The scaffolds water content and mass retention were 
calculated over time from measurements of wet and dry masses. Part (A) shows the water 
content, while part (B) shows the mass retention. Equilibrium water content is reached 
quickly (1-2 days), and in all cases the scaffolds do not loose a large amount of mass like 
the PHEMA-PEG scaffolds. 
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Figure 29 The swelling properties of the 80% solvent PHEMA-PVA scaffolds. 
80% solvent PHEMA-PVA scaffolds with increasing (wt/vol)% microparticles were 
immersed in PBS at 370C. The scaffolds water content and mass retention were 
calculated over time from measurements of wet and dry masses. Part (A) shows the water 
content, while part (B) shows the mass retention. Equilibrium water content is reached 
quickly (1-2 days), and in all cases the scaffolds do not loose a large amount of mass like 
the PHEMA-PEG scaffolds. 
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Figure 30 The morphology of the PNIPAAm-PEG scaffold.   
SEM of a flash frozen, then lyophilized scaffold made from PNIPAAm-PEG(8000) 700:1 
shows that this polymeric hydrogel exhibits an interconnected macroporous structure.  
The scaffold is not as porous as the previously studied PHEMA-PEG and PHEMA-PVA 
scaffolds. Some pore morphology may be lost in the flash freezing process, but was 
found necessary to stabilize the scaffold for viewing. 
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Figure 31 The morphology of the PNIPAAm-PEG scaffold with incorporated 
microparticles.  
SEM of a flash frozen, then lyophilized scaffold made from PNIPAAm-PEG(8000) 700:1 
with incorporated microparticles shows that this polymeric hydrogel is also able to 
physically entrap microparticles (arrow). The microparticle in this scaffold appears to 
have degraded some, which is to be expected since this scaffold was immersed in PBS for 
14 days prior to imaging, and since the PLA polymer is sensitive to the electron beam 
used in the SEM. 
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Table 4 The LCST and compressive modulus of PNIPAAm-PEG with incorporated 
microparticles. 
The compressive modulus and lower critical solution temperature (LCST) were 
determined for the PNIPAAm-PEG (8000) scaffold at 700:1 monomer ratio with 
increasing (wt/vol) % microparticles added to the aqueous solution (10 wt% in PBS). The 
addition of microparticles did not affect the LCST, however, increasing microparticles 
did exhibit a direct correlation with increasing compressive modulus. 
Sample Compressive Modulus (kPa) LCST ( C )
Control 2.2 +/- 0.6 30.7 +/- 0.3
5% 2.6 +/- 0.8 30.1 +/- 1.1
10% 4.6 +/- 0.2 30.5 +/- 0.4
20% 6.1 +/- 0.4 30.6 +/- 0.3
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Figure 32 The swelling properties of PNIPAAm-PEG scaffolds.  
PNIPAAm-PEG (8000) (700:1) scaffolds with increasing (wt/vol)% microparticles were 
immersed in PBS at 370C. The scaffolds water content, mass retention and volume 
retention were calculated over time from measurements of wet and dry masses. Part (A) 
shows the water content, while parts (B) and (C) show the mass and volume retention 
respectively. Equilibrium water content is reached quickly (1-2 days), and in all cases, the 
scaffolds are able to maintain both their mass and volume post injection.  
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4.4 Discussion 
 
4.4.1 PHEMA-PEG scaffolds 
It is believed that this large mass loss is due to the 50% glycerol in the solvent 
phase of the scaffolds. The scaffolds “dump” the glycerol into the PBS almost 
immediately upon swelling due to osmotic driving forces. This is not a desirable result 
for a biomaterial which should not release anything but the loaded drug.  The scaffolds do 
reach equilibrium quickly (1-2 days) and can be designed to match the order of 
magnitude of the natural tissue (75% scaffolds are in the 3-5kPa range). The addition of 
microparticles to these scaffolds has no clear effect on the mechanical or swelling 
properties of the scaffold. This is because the large pore structure and high water content 
of the scaffolds dominates the mechanical strength and swelling ability of the polymeric 
scaffold. However, because of the large mass loss shown in the swelling studies a 
different scaffold system in which a surfactant for microparticle dispersion is not 
necessary was deemed necessary.  
 
4.4.2 PHEMA-PVA 
 The next scaffold investigated was the PHEMA-PVA, which incorporated a 
surfactant in the reaction mixture by changing the crosslinking reagent from 
dimethyacrylated PEG to methacrylated PVA. The PVA acts as not only crosslinker for 
the PHEMA but also a surfactant for the incorporated microparticles.  
The addition of microparticles effect on the mechanical properties of these 
scaffolds can be seen in the 70 vol% scaffolds since they have the stiffest modulus due to 
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their lower porosity and lower water content. The addition of microparticles in these 
scaffolds therefore affects the pore structure leading to a softening of the scaffolds. The 
75 and 80% scaffolds moduli were dominated by their large water content and therefore 
not affected by the addition of the microparticles.  
The swelling results for the PHEMA-PVA were similar to that for PHEMA-PEG 
that was to be expected since the large macropores and high water contents are similar 
between these scaffolds. These scaffolds show great promise for tissue engineering 
applications because of their high water contents, macroporous structures, ability to 
easily incorporate microparticles and adaptable compressive modulus. The ability of the 
scaffold to maintain is mass and volume over time is also a positive result for tissue 
engineering applications as well as its ability to reach equilibrium quickly. 
 
4.4.3 PNIPAAm-PEG 
 The final scaffold system evaluated was an injectable scaffold made from 
PNIPAAM-PEG. This is a branched copolymer that is desirable for an injectable scaffold 
since it exhibits an LCST between 32-340C. The ratio of monomers as well as the PEG 
branch length could be altered in order to change the scaffolds mechanical properties.  
The copolymer was chosen based upon the ability to create a macroporous scaffold since 
previous polymer scaffold work showed the change in water content dominates the 
scaffolds compressive strength. Therefore for neural tissue engineering applications, the 
PNIPAAm-PEG(8000), with a 700:1 monomer ratio is the only scaffold investigated. 
 The PNIPAAm-PEG scaffold can easily be adapted to reach the desired 
compressive strength, as well as maintain its mass and volume over time.  The presence 
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of microparticles throughout the solution did not affect the copolymer’s LCST, mass or 
volume retention. The addition of microparticles adds stability to the crosslinked scaffold 
by increasing the polymer content and thereby increasing its mechanical strength. A 
direct correlation with increasing microparticle content and compressive strength is 
exhibited in these scaffolds.  
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4.5 Conclusions 
 
Although all three scaffolds investigated showed macroporous structures that 
were able to incorporate microparticles, the main goal of this chapter was to determine 
which scaffold is best suited for neural tissue engineering? More directly, which scaffold 
should move forward to animal studies?  The most desirable property for the animal 
studies is a scaffold that is easily implantable into the injury site. The scaffold must retain 
its mass and volume over time in vivo and should not leach anything into the animal’s 
spinal tissue other than the desired therapeutic drugs.  
Using these guidelines, the PHEMA-PEG scaffold can be eliminated since it 
leached the glycerol phase during swelling in vitro. The PHEMA-PVA scaffold would 
eliminate these problems, however, its ability to adapt to an irregular shaped injury site in 
the spinal tissue is questionable. The ability to mold a scaffold small enough to fit into a 
rodent spinal cord is also extremely difficult, since the volume of the injury is on average 
3-5 µL. This requirement lead to the decision that an injectable scaffold design that could 
be molded to the injury site, but also met the same requirements as the traditional 
implantable designs would be the best choice. Therefore, for all further studies, the 
PNIPAAm-PEG (8000) is the only scaffold tested.  
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Chapter 5 In vitro evaluation of multifunctional 
PNIPAAm-PEG scaffolds  
 
 
 
5.1 Introduction 
 Tissue engineering is emerging and exciting research topic in the field of 
biomaterials, but the remaining challenge is to elucidate a translation direction.  This is 
because of large number of the designs proposed in current literature focus on 
microstructure design of porous scaffolds or channels that must be conditioned ex vivo 
prior to implantation.  These are not only complicated, but can be very difficult to 
achieve surgically. However, if a scaffold could be designed more simply and robustly 
that could adapt to different injury sizes and cellular needs, this would be an ideal 
solution. 
 It is proposed that the thermally responsive poly (N-isopropyl)-graft-
poly(ethylene glycol) (PNIPAAm-PEG) can function as an injectable multifunctional 
scaffold for tissue engineering applications.  Below its lower critical solution temperature 
(LCST), typically around 29-32°C, the polymer forms a miscible solution with water, but 
above its LCST, it becomes hydrophobic, separating from water and forming a 
semiporous gel.  Since the polymeric scaffold is semiporous it can easily provide for cell 
growth and proliferation. Because of the nature of this polymer, cells and neurotrophins 
can be mixed with the polymer in solution at room temperature or below and then 
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delivered in a minimally invasive fashion to provide a space-filling scaffold that molds 
itself to the site of injury.  
 These studies aim to provide a proof of concept that the scaffold can be created in 
an aqueous environment made from cell culture medium (containing extra salts, peptides 
and proteins),  and incorporate viable cells that can proliferate in the scaffold. The 
scaffolds ability to act as its own controlled drug delivery vehicle will also be assessed. 
The goals of this work were specifically to answer the following questions: 
1. Does the addition of extra salts or serum proteins affect the properties of the 
PNIPAAm-PEG gel? 
2.  Does the scaffold provide a compatible environment for cellular growth? 
3. Can the scaffold provide a sustained release of trophic factors? 
4. Are the released trophic factors still biologically active? 
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5.2 Experimental Section 
5.2.1 Swelling properties of PNIPAAm-PEG in different immersion 
media 
PNIPAAm-PEG scaffold samples were molded in 24 well tissue culture dish at 
37oC for one hour. Samples were immersed in ~15mL of DMEM/F12 (Invitrogen) or 
DMEM/F12 + 16.6% fetal bovine serum (FBS, Hyclone) at 37oC and at desired time 
points were massed in air (Mair) and in n-heptane (Mheptane) in order to determine the 
density (ρ) and volume (V) of the scaffolds over time. An initial wet mass in air and 
heptane prior to immersion was taken for each sample as the initial value (t=0).  The 
mass and volume retention were taken to be the ratio of mass (or volume) at time t to 
mass (or volume) at time zero.   
 
5.2.2 Mechanical testing 
The compressive moduli of all samples were evaluated after swelling in PBS at 
370C using an Instron mechanical testing system (Model 4100, Series IX software, Park 
Ridge, IL).  Cylindrical scaffold samples were tested in a custom made immersion bath 
that allowed for samples to be immersion in PBS at 37oC. Samples were compressed at a 
strain rate of 100% per minute and load versus displacement data were collected. The 
load and displacement could be converted to stress versus strain by using the 
premeasured dimensions of each sample. The compressive modulus was taken as the 
slope of the linear region of the stress-strain curve (from 0-15% strain).  
Lower critical solution temperature determination 
The lower critical solution temperature (LCST) of the PNIPAAm-PEG solutions 
was found using a Differential Scanning Calorimeter from TA Instruments (Model # 
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2010, Wilmington, DE). A 10mg sample was placed in an allodized aluminum pan that 
was hermetically sealed then heated from 10 to 600C at 100C per minute. The onset 
temperature for the endothermic phase transition on the DSC thermograph was taken to 
be the LCST. 
 
5.2.3 Cell culture 
5.2.3.1  Marrow stromal cells (MSC’s) 
 Cryopreserved MSC were thawed quickly at 370C and plated in α-MEM 
(Invitrogen) supplemented with 16.6 % fetal bovine serum (FBS) (Invitrogen) on 100-
mm plastic dishes. The same lot of serum was used for all experiments. The serum lot 
chosen allowed consistent, rapid growth and proliferation of MSC. Prior to grafting, 
cultures were incubated with a fluorescent dye to allow detection. The following day, 
cells were washed several times with HBSS and then removed from the culture plates 
using 0.1% trypsin/EDTA (Cellgro, Herndon, VA). MSC were then re-suspended in the 
copolymer solution at 1 million cells per 2mL for in vitro studies. 
 
5.2.3.2 Mixed neuronal- and glial -restricted precursor cells 
(NRP/GRP’s) 
  NRP/GRPs were isolated from E13.5 transgenic Fischer 344 rats that express the 
alkaline phosphatase (AP) marker gene1-3. Briefly, embryos were isolated and incubated 
in collagenase type I/dispase II to allow for removal of meninges. Cords were dissociated 
using a 0.5 % trypsin/EDTA (invitrogen) solution for 20 minutes at 370C and then plated 
in NEP basal medium (with  BSA at 1mg/mL, Sigma) supplemented with bFGF  and NT-
3 (10ug/mL each, Preprotech, Rocky Hill, NJ) on dishes coated with poly-L-lysine and 
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laminin4.  Fresh media was added to culture plates every 48 hours. Cells were removed 
from the plates using 0.1% trypsin/EDTA (Cellgro), washed with PBS and then added to 
the copolymer solution at one million cells per 2mL sample . 
 
5.2.4 Polymer cell viability in vitro 
 Cells were added at 1 million cells per 2 mL sample. The cell count of viable cells 
was found using trypan blue (Invitrogen) and a hemocytometer.  Cells were washed in 
PBS and pelleted prior to resuspending in the 10 wt% aqueous polymer solution, made 
from DMEM-F12 cell culture media with 16.6% FBS. The scaffolds were molded in 12 
well culture dishes at 370C and then transferred to a larger culture dish with excess 
culture media in order to support the cell growth. The media added to scaffold systems 
also included penicillin-streptomycin as used routinely in cell culture.  The viability of 
the cells within the scaffold was assessed over time with a dual fluorescent stain (LIVE- 
DEAD assay) for both live and dead cells. This allowed the cells to be viewed while in 
the opaque solid hydrogel. Briefly, the media was removed from the desired sample, and 
it was washed once with warm cell culture grade phosphate buffer. The staining solution 
was mixed per the manufacturers (Invitrogen) directions and the sample was incubated in 
the stain for 2 hours at 370C and 5% CO2 prior to imaging on an inverted fluorescent 
microscope.  
 
5.2.5 Release and Bioactivity of trophic factors from the scaffold 
To assess if neurotrophins released from the scaffold are biologically active, a 
chick dorsal root ganglion (DRG) explant bioassay evaluating neurite outgrowth will be 
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used. Fertilized eggs obtained from SPAFAS (Preston, CT) were incubated in a 
humidified incubator at 37°C for 8 days. Eggs containing E10 embryos were opened, and 
the embryo removed to a sterile Petri dish containing pre-warmed DMEM with 0.1% 
heat-inactivated goat serum. Meninges and connective tissue were removed and lumbar 
DRG dissected out. DRG explants were cultured in poly-L-lysine-coated 24-well dishes 
for bioactivity assays. BDNF and NT-3 induced neurite extension were tested as 
described by previous researchers5.  Polymer scaffolds made from 10-wt% aqueous 
PNIPAAm-PEG (8000 Mw, 700:1) in DMEM/F12 media were molded in 12-well dishes 
and maintained at 370C and 5% CO2 with appropriate media, as explained in the table 
5.1. 
 Medium will be conditioned for 3 days prior to analysis for neurotrophin bioactivity 
after 3 days and after 4 weeks. DRG explants will be exposed to 500 µl of each sample 
media (for a total of n=6 each) and DMEM/F12 media with 100ng/mL of both BDNF and 
NT-3 will serve as positive controls for neurite outgrowth. DRG will be fixed in 0.25% 
glutaraldehyde after 48 hours of incubation in 37°C at 5% CO2 and neurite outgrowth in 
each well will be examined. Images will be obtained using an Olympus CK40 
microscope with a 10x phase objective connected to a Nikon Coolpix 990 digital camera 
was used for analysis. To determine the average length of axons extended from each 
DRG, the distance from the edge of the explant to the main field of growth cones was 
measured in four places around the perimeter by using a micrometer slide. The average of 
the four measurements and the standard error were calculated for each experiment [57].  
 Samples of the conditioned media were taken each time fresh media was added to 
the hydrogel samples and stored at 40C.  After collection, samples were thawed and run 
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on a sandwich enzyme linked immunosorbent assay (ELISA) for BDNF and NT-3 
concentrations (R&D Systems). Kits were used per manufacturers instructions. 
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5.3 Results & Discussion 
5.3.1 Does the addition of extra salts or serum proteins affect the 
properties of the PNIPAAm-PEG gel? 
 Since the goal of these studies was to find a scaffold that was best suited for 
moving forward to cell and animal studies, it was critical to evaluate the effect of 
additional salts and serum proteins that would be seen in vitro and in vivo.  The 
PNIPAAm-PEG scaffold was created using three different aqueous solutions to draw 
these comparisons. The scaffold was made, as previously studied using PBS, as well as in 
DMEM/F12 cell culture media and DMEM/F12 with fetal bovine serum (FBS). The 
resulting scaffolds were tested for their LCST, compressive moduli and swelling 
characteristics as described previously. 
The results in table 5.2 show that changing the aqueous solution media did not 
have an effect on the on LCST of the polymer solution, however did change the 
compressive moduli. The presence of serum proteins overall softens the scaffold by 
acting as a plasticizer during the phase separation and preventing physical crosslinks 
from occurring.  The swelling characteristics of the scaffolds in the DMEM/F12 media 
and media with FBS are seen in figure 5.1.  The scaffolds all maintained their mass and 
volume over time similar to the results seen in PBS (found in Chapter 4). 
 
5.3.2. Does the scaffold provide a compatible environment for cellular 
growth? 
 A critical parameter in the design of the multifunctional scaffold system is that the 
hydrogel function as a cell transplant device. In order for the scaffold to support cells for 
transplant, in vitro polymer-cell compatibility was tested with two different cell lines. 
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The two cell types chosen, marrow stromal cells (hMSC) and mixed neural and glial 
restricted precursor cells (NRP/GRP) both have great potential in tissue engineering 
applications. The scaffolds were made using the aqueous polymer solution (made from 
10 wt% PNIPAAm-PEG in DMEM/F12 media) with 1x106 cells (either hMSC or 
NRP/GRP) incorporated.  The cell viability was assessed using a dual fluorescent stain 
for live and dead cells within the scaffold at different incubation times.  
The results for the hMSC’s can be seen in figure 5.2, where the live cells are 
stained green and the dead cells are stained red.   There are a relatively large number of 
live cells after three days incubation, with some dead cells. The live cells, however, do 
not attach to the scaffold and resemble their normal morphology until day 14.  By 31 
days incubation, without replating the cells, the embedded cells within the scaffold have 
not only survived, but also attached to the scaffold and appear to have proliferated. 
Similarly, figure 5.3 shows the results for the NRP/GRP cells after 5, 7, 14 and 31 
days of incubation. A smaller number of the NRP/GRP cells survive in the scaffold 
initially, however, at 7 and 14 days these cells start to grow processes. By 31 days of 
incubation some of the cells have the neuron morphology.  
 These results show that the scaffold can support two very different cell lines for 
up to 31 days in vitro, without passage. The cells are able to survive while entrapped in 
the scaffold, as well as attach and move the scaffold to grow and extend processes. 
Although the results are only qualitative, and no actual quantitative number can be found, 
there is good evidence that the cells are proliferating in the scaffold.   
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5.3.3. Can the scaffold provide a sustained release of trophic factors? 
 In order to determine the release profile from the in vitro scaffold system, 
scaffolds were made with NT-3 (25ug),BDNF (25 ug), hMSC (1x106 cells), or NRP/GRP 
(1x106 cells).  Scaffolds were immersed in 2mL of the appropriate media and fresh media 
was added every 2-3 days,  while the old media samples were kept frozen. When all 
media were collected, they were thawed and anaylzed on either an NT-3 or BDNF 
specific enzyme linked immunosorbent assay (ELISA). The two cell lines were run on 
both the NT-3 and the BDNF ELISA, however no detectable release of these trophic 
factors was seen within the working range of the ELISA (pg/mL).  
The results for the release of the NT-3 from the scaffold can be seen in Figure 5.4. 
This result shows that the scaffold clearly provides a controlled, almost linear release of 
the trophic factor for up to four weeks. If the trend is followed, 100% release is predicted 
to take 6 weeks. The scaffold gives only a minimal burst in the first three days of around 
10%. This extended release in vitro from the scaffold can be explained by the slightly 
hydrophobic property of the PNIPAAm. This allows the cells and trophic factors to 
remain physically entrapped in the scaffold and are slowly release over time by diffusion.   
 
5.3.4. Are the released trophic factors still biologically active? 
 Although extending the release of the trophic factors after an injury is critical, the 
more important question is whether the release trophic factors still biologically active?  In 
order to determine if the released trophic factors were active, media samples from the 
previous release study were taken and immediately applied to cultured DRG explants for 
two days. This provided enough time for the cultured DRG’s to attach and extend 
processes if there was sufficient active trophic factor present (at least 1-10ng/mL). Since 
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our release was designed to be at the ug/mL concentration, if only 0.1% of the released 
trophic factors remained active, growth would be seen from the DRG’s.  Negative 
controls (of just the scaffold with each media) as well as a positive control (DMEM/F12 
with 100 ng/mL of both NT-3 and BDNF) were analyzed as well.   
 A picture of a representative DRG from the NT-3, BDNF and the negative control 
can be seen in figure 5.5. The process growth was averaged over the different samples 
and can be seen in figure 5.6.  The NT-3 and BDNF both showed statistically significant 
growth compared to the media alone, meaning the trophic factors released still had some 
bioactivity remaining. The hMSC also had a significant process extension as compared to 
its media, meaning the MSC’s are releasing trophic factors at high enough of a level to 
elicit a response for up to 31 days, however it is not clear what trophic factors are being 
released that elicited that response from this study. The NRP/GRPs however, did not 
show a significant difference between the cells and the media alone and therefore were 
not releasing enough trophic factor to create a response from the DRG’s. 
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Group Medium Recipe 
 2ml media 0.5 ml gel + 
DRG + Hydrogel (neg. control) DMEM/F12 ----------- 
DRG + Hydrogel (neg. control) αMEM + 
10% FBS 
---------- 
DRG + Hydrogel (neg. control) NEP basal ----------- 
DRG + Hydrogel + NT-3 DMEM/F12 5uL of NT3 (25ug in 
5uL dH20) 
DRG + Hydrogel + BDNF DMEM/F12 10uL of BDNF (25ug in 
10uL dH20) 
DRG + Hydrogel + hMSC (GFP) αMEM + 
10% FBS 
1x10^6 MSC’s in pellet 
DRG + Hydrogel + NPC  NEP basal 1x10^6 NPC’s in pellet 
DRG + NGF (pos. control)  DMEM/F12  NO GEL 
 
Table 5.1 The experimental setup for bioactivity of trophic factor release. 
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Table 6. The material properties of PNIPAAm-PEG(8000) in different immersion 
media. Scaffolds were prepared by injecting a known mass of 10wt% polymer solution 
(made from one of the three immersion media) then immersed in the same media for 
seven days prior to uniaxially compressing to find the compressive moduli. The moduli 
were taken as the slope from 0-15% strain. The LCST was found from the onset 
temperature of the phase transition in the DSC thermogram. 
Immersion media Compressive modulus (kPa) LCST (0C) 
PBS 2.2 +/- 0.6 31 +/- 0.5 
Media 3.8 +/- 0.7 31 +/- 1.3 
Media with serum 1.4 +/- 0.7 30 +/- 1.8 
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Figure 33 Swelling in media with serum. Mass and volume retention over immersion 
time are show in part (A) and (B) respectively for scaffolds immersed in DMEM/F12 
media with and without 16.6% FBS as compared to PBS.  
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Figure 34 Polymer-cell viability with MSCs.  Live cells are stained green and dead 
cells are stained red. Images were all taken at 20x phase objective. The images show the 
cell viability at 5, 7, 14 and 31 days of incubation in the polymer scaffold in vitro. 
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Figure 35 Polymer-cell viability with NPCs.  Live cells are stained green and dead cells 
are stained red. Images were all taken at 20x phase objective. The images show the cell 
viability at 5, 7, 14 and 31 days of incubation in the polymer scaffold in vitro. 
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Figure 36  Trophic factor release from the PNIPAAm-PEG scaffold in vitro.   NT-3 
release (triangles) was found using ELISA on n=2 samples and error bars shown are the 
standard deviation. 
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Figure 37 Representative DRG neurite growth.  Images were taken using a 10x optical 
microscope and show the representative neurite outgrowth from DRG’s exposed to NT-3 
release media, BDNF release media and DMEM/F12 media (- control). 
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Figure 38 Neurite extension from cultured DRG explants.  The average neurite 
extension from the culture DRG explants exposed to the different sample media are 
shown for n=5. The positive control (NT-3, BDNF 100ng/mL each) and negative controls 
(DMEM-F12, αMEM, NEP basal media) were run. The NT-3, BDNF, and hMSC all 
showed statistically significant growth compared to their respective media.  
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 5.4 Conclusions 
 The purpose of these studies was to evaluate the thermoreversible PNIPAAm-
PEG scaffold as a host environment for cellular growth and proliferation in vitro. 
Mechanical and swelling studies in performed in DMEM/F12 media with and without 
serum showed that the presence of the extra salts did not greatly affect the scaffolds 
swelling properties or transition temperature. The presence of serum proteins acted as a 
plasticizer, decreasing the stiffness of the scaffold, however, it still remained on the order 
of magnitude necessary for neural tissue engineering applications.  
 The incorporation of cells was successfully done with two very different cell lines 
showing the robustness of the scaffold as a cellular support matrix. The choice of cell 
types evaluated, adult stem cells of messenchymal lineage (MSCs) and fetal stem cells of 
the central nervous system lineage (NRP/GRPs) was due to their promise as regenerative 
transplants for tissue engineering (especially spinal cord repair). The MSCs are a 
clinically attractive cell type because of the possibility of autologous use, meaning they 
could be harvested prior to surgery from the patient themselves. The MSCs have been 
proposed for use in CNS injury as well as cartilage and bone tissue engineering 
strategies. The NRP/GRPs are an exciting cell type that can potentially be used for 
cellular replacement strategies in CNS injury or disorders, such as Alzheimer’s and 
Parkinson’s disease.  
The cell survival, along with the prolonged linear release of trophic factors 
provided by the scaffold show that PNIPAAm-PEG makes an excellent choice for a 
multifunctional cell-polymer matrix design. The ability of the cells to adapt the scaffold 
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morphology to match their needs during growth only makes the scaffold more attractive, 
because it eliminates the need to over-design channels or pore structures a priori.  The 
simple combination of the cells and trophic factor with the viscous polymer solution prior 
to injection makes this design extremely advantageous in the hopes of one day becoming 
a clinical possibility.  
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Chapter 6 In vivo evaluation of multifunctional 
PNIPAAm-PEG scaffolds for spinal cord repair 
 
 
 
 
6.1 Introduction 
Spinal cord injury (SCI) affects approximately 10,000 individuals in the United 
States every year. SCI occurs most commonly in young adults, leaving them seriously 
disabled for the remainder of their lives. Apart from paralysis, SCI patients suffer from 
additional disabilities including bladder, bowel and sexual dysfunction, and neuropathic 
pain syndromes. Several potentially useful therapeutic strategies have emerged over the 
last decade. These include delivery of neurotrophic factors and other therapeutic proteins, 
and use of cellular transplants and synthetic matrices and scaffolds to promote neuronal 
regeneration and functional recovery1, 2. The basic approach to tissue engineered designs 
for spinal cord repair has been to create an environment ex vivo that is favorable for 
cellular growth and is permissive for axon growth prior to transplanting into the injury 
site. These designs have been primarily one of three types, either a scaffold free cellular 
transplant, an acellular engineered scaffold, or a combination cell and scaffold transplant. 
The goal of these designs is to surgically stabilize the injury site, and create a more 
permissive environment for axonal regeneration. 
While progress has been made, many challenges still remain, notably the surgical 
difficulties involved in the implantation of rigid scaffolds that can result in further 
damage of the already compromised cord. Other limitations include the survival of 
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transplanted cells in the hazardous injury environment that is comprised not only by 
reactive astrocytes and macrophages, but also signals for apoptosis and necrosis (suicide 
versus murder: apoptosis  is programmed cell death while necrosis is caused by physical 
damage that kills the cell). Little progress has been made in the prevention of the physical 
barrier created by the glial scar, which is believed to be a barrier to regeneration. 
Here we propose to develop a novel, injectable scaffold containing stem cells and 
neurotrophic factors.  Two different stem cell lineages will be tested; adult messenchymal 
lineage (human bone marrow stromal cells-MSCs) as well as fetal nueral lineage (rat 
emybronic neural precuror cells-NPCs). The use of a multifunctional scaffold containing 
a combination of these strategies, which can potentially act synergistically may lead to 
greater therapeutic efficacy.  This scaffold will provide mechanical support to the injury 
site, allow the delivery of cell transplants to the injury, and provide a locally sustained 
release of neurotrophins. The multifunctional scaffold thereby ensures a permissive area 
for the regeneration of injured axons by creating a polymeric-cellular bridge.  The 
scaffold will be a permanent graft that does not biodegrade since the constant erosion of 
the matrix over time may lead to increased inflammatory response and formation of an 
extended glial scar.  It is proposed that the removal of the scaffold, which is designed for 
celluar adherence, could be detrimental. 
The proposed scaffold is made from a thermally responsive, injectable polymer, 
poly (N-isopropyl)-graft-poly(ethylene glycol) (PNIPAAm-PEG).  Below its lower 
critical solution temperature (LCST), typically around 29-32°C, the polymer forms a 
miscible solution with water, but above its LCST, it becomes hydrophobic, separating 
from water and forming a semiporous gel.  Since the polymeric scaffold is semiporous it 
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can easily provide for cell growth and proliferation.  Additionally, it can be engineered to 
match the mechanical properties of the native neural tissue. This is of great importance, 
since many previously failed attempts have shown that mechanical matching is a critical 
parameter in implant design3.  Because of the nature of this polymer, cells and 
neurotrophins can be mixed with the polymer in solution at room temperature or below 
and then delivered in a minimally invasive fashion to provide a space-filling scaffold that 
molds itself to the site of injury.  In this work two different cell types will be tested with 
the scaffold. This asses not only the robustness of the scaffold as a cellular transplant 
device, but also a direct comparison of two different cellular approaches.  
One of the cell types evaluated is marrow stromal cells (MSCs). The 
incorporation of MSCs provides production of extra cellular matrix, and other support 
molecules for axon growth. The other cellular approach is the mixed neuronal- and glial- 
restricted precursor cells (referred to as simply neural precursor cells or NPCs). NPCs can 
differentiate into neurons and glia, creating an environment that resembles the intact CNS 
with the potential to replaced damaged tissue and make connections with host neurons. 
Such connections could ultimately lead to a restoration of long-distance tracts via the 
formation of neuronal relays. 
In order to provide a permissive environment for axon growth, trophic factors 
must be present. Since the direct injection of these trophic factors, such as brain derived 
neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) lead to saturation of the local 
tissue which does not support growth, the inclusion of these trophic factors into the 
scaffold is desirable. Since the polymeric scaffold is hydrophobic, it sufficiently traps the 
trophic factors within its matrix after injection, slowly releasing them to the local tissue. 
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This provides a mechanism to draw axons into the scaffold (where the trophic factors are 
localized) but also provides an opportunity for axons to exit the scaffold to the local 
tissue after the prolonged release subsides. 
It is therefore hypothesize that localized, sustained, simultaneous delivery within 
a window of 2-4 weeks of multiple therapeutic proteins into the CNS along with an 
injectable polymeric-cellular scaffold creates a synergistic effect by synchronously 
modulating the injured environment and activating different signaling pathways. By 
engineering this injectable hydrogel and cellular based scaffold to mimic the host tissues 
we can create a novel platform technology with applications in treatment of SCI and 
other tissue engineering applications. 
The goals of this work were specifically to answer the following questions: 
1. Is the injectable PNIPAAm-PEG scaffold surgically realizable? 
2. What is the host response to the PNIPAAm-PEG scaffold? 
3. Can the two cell types survive within the scaffold in vivo? 
4. Can axons grow into the scaffold? 
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6.2 Experimental Section 
6.2.1 Copolymer synthesis  
Poly ethylene glycol dimethacrylate (PEGDM) molecular weight 8000 was 
synthesized by reacting PEG (8000) diol with an excess of methacylrylol chloride under 
anhydrous conditions as described by Bryant et al4.  The efficiency of this reaction was 
assessed using 1H NMR (Varian 300, Palo Alto, CA) and comparing the integral area 
under the peak for the vinyl protons to area of the PEG protons5. Poly (N-
isopropylacrylamide)-g-poly (ethylene glycol) (PNIPAAm-PEG) copolymer was 
polymerized as previously described by Vernengo, et al5.  Briefly, the NIPAAm 
monomer was mixed with PEGDM (8000) at a 700:1 monomer ratio in methanol and the 
free radical polymerization was thermally initiated by azobisisobutylnitrile (AIBN) at 
650C. The reaction was allowed to go until completion (48hrs) prior to removal of excess 
methanol through evaporation. The copolymer was ground and purified by washing with 
hexane and dried. 10 wt% aqueous polymer solutions were made using DMEM-F12 
media (Invitrogen) with fetal bovine serum (Hyclone).  The molar ratio of the 
PNIPAAm:PEG was assessed using proton NMR, and found to be 735:1 for the 
copolymer batch used in all in vivo studies.  
 
6.2.2Cell culture 
6.2.2.1  Marrow stromal cells (MSC’s) 
 Human bone marrow stromal cells were harvested from volunteers, cultured and 
donated for use by Dr. Prokup, Tulane Center for Gene Therapy. Cultures were incubated 
with a fluorescent dye (green fluorescent protein-GFP) for imaging (Dr. Prokup, Tulane 
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Center for Gene Therapy). Cryopreserved human MSC were thawed quickly at 370C and 
plated in α-MEM (Invitrogen) supplemented with 20% FBS and 4 mM l-glutamine 
(Invitrogen) on 100-mm plastic dishes. The same lot of serum was used for all 
experiments. The serum lot chosen allowed consistent, rapid growth and proliferation of 
MSC. The following day, cells were washed several times with HBSS and then removed 
from the culture plates using 0.1% trypsin/EDTA (Cellgro, Herndon, VA). MSC were 
then re-suspended in the copolymer solution at 100,000 cells/3uL and maintained on ice 
during transplantation surgery. 
 
 
6.2.2.2 Mixed neuronal- and glial -restricted precursor cells 
(NRP/GRP’s) 
  NRP/GRP’s were isolated from E13.5 transgenic Fischer 344 rats that express the 
alkaline phosphatase (AP) marker gene6-8. Briefly, embryos were isolated and incubated 
in collagenase type I/dispase II to allow for removal of meninges. Cords were dissociated 
using a 0.5 % trypsin/EDTA (invitrogen) solution for 20 minutes at 370C and then plated 
in NEP basal medium (with  BSA at 1mg/mL, Sigma) supplemented with bFGF  and NT-
3 (10ug/mL each, Preprotech, Rocky Hill, NJ) on dishes coated with poly-L-lysine and 
laminin9.  Fresh media was added to culture plates every 48 hours. All cells prepared for 
surgery were grown for 6 days prior to transplantation. 
 
6.2.3 Surgery   
The animal model chosen for this study was a partial hemi-section in adult female 
Sprague–Dawley rats (approximately 250 grams) at the C4-C5 range, and was based 
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upon previous work done by Lepore et al10.  This surgical lesion was chosen because it 
creates a precise injury site that is useful in studying the regeneration of the host axons. 
The clear cavity created by the injury is also a desirable model for a space filling 
hydrogel design. Animals were anesthetized with intraperitoneal injection of an analgesic 
cocktail [acepromazine maleate (0.7 mg/kg; Fermenta Animal Health, Kansas City, MO), 
ketamine (95 mg/kg; Fort Dodge Animal Health; Fort Dodge, IA), and xylazine (10 
mg/kg; Bayer, Shawnee Mission, KS)] and a C4/5 laminectomy was performed. Briefly, 
the spine was exposed and the lateral funiculus of the C4/5 spinal cord was aspirated 
selectively removing the white matter in the lateral spinal tracts, specifically the 
rubrospinal tract. The scaffold was injected into the surgical cavity, and the dura, muscle 
and skin surgically closed. Animals were given one of the following injections (n=6 for 
each) described in the table 6.1. 
All injections were 3-5 uL, and done using a physical displacement pipette to 
minimize bubbles in the injected solution. For those that included either cells or trophic 
factors, cells were at a concentration of 100,000 cells/3uL and NT-3 and BDNF were at 
50 ug/mL. Beginning three days prior to surgery animals were immunosuppressed by 
subcutaneous administration of cyclosporine A (1 mg/kg body weight; Sandoz 
Pharmaceuticals, East Hanover, NJ), which was continued daily until sacrifice. All 
animals received appropriate analgesia, antibiotics and post-operative care according to 
the guidelines set by the Drexel University IACUC and the Institute of Laboratory 
Animal Resources, U.S. National Academy of Sciences. 
Another two week study was done using the same animal model, however 
injections were one of the following matrices: PNIPAAm-PEG, Vitrogen® (Cohesion, 
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Palo Alto, CA), or Gelfoam® (Pfizer). Vitrogen® is a collagen based matrix, while 
Gelfoam® is a degradable gelatin sponge.  Both commercially available matrices were 
used as a base comparison of the host response to the PNIPAAm-PEG. 
 
6.2.4 Tissue processing  
Animals were euthanized and transcardially perfused using room temperature 4% 
paraformaldehyde in 0.1M sodium phosphate buffer, pH 7.4. Spinal cords were removed, 
fixed in 4% paraformaldehyde for 3 days at 4ºC followed by cryoprotection in 30% 
sucrose at 4ºC for 5 days. The tissue was be embedded in M-1 media (Thermo Shandon), 
fast frozen with dry ice, and stored at –70ºC until processed. Spinal cord tissue blocks 
were cut in the sagittal plane at 20-µm thickness. Sections were collected on poly-L-
lysine-coated glass slides and stored at 4ºC until analyzed.  
 
6.2.5 Graft survival analysis 
 MSC graft survival was analyzed using fluorescence microscopy, under a FITC 
filter cube, since cells transplanted were green fluorescent protein (GFP) positive. For 
further amplification of this signal, immuno staining of some sections was done using a 
mouse anti-GFP antibody, followed by a similar immuno staining protocol as described 
in 5.2.e. 
NRP/GRP graft survival and migration was evaluated using alkaline phosphatase 
histochemistry. Tissue sections were washed in PBS, heated to 600C for one hour to 
inactivate any endogenous enzyme activity prior to treating with alkaline phosphatase 
buffer (Tris (100mM, pH 9.5, Fisher), NaCl (100mM, Fisher), MgCl2 (50mM, Fisher)). 
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Sections were then incubated at room temperature in the dark with alkaline phosphatase 
staining solution (NBT (1mg/mL ,Sigma), BCIP (0.1mg/mL, Sigma), levamisole (5mM, 
Sigma) for 2 hours. Slides were then coverslipped in hardest Vectashield (Vector 
laboratories, Burlingame, CA) and viewed using light microscopy.  
 
6.2.6 Injury size 
Every sixth section through the lesion site was histological stained with 
Nissl/myelin to highlight the white matter of the spinal cord. This allowed clear imaging 
of the injury site and the size of the injury four-week post operation. All slides were 
dehydrated and coverslipped with DPX prior to imaging on a bright field Lecia DM5500 
Microscope (Leica Microsystems, Bannockburn, IL).  
 
6.2.7 Fluorescence immuno staining and immunohistochemistry for 
analysis of host tissue  
Slides with tissue sections were washed in PBS with 0.2% triton, and nonspecific 
staining was blocked via incubation in 10% goat serum (Invitrogen) for 1hr at room 
temperature. Sections were incubated in their primary antibody over night in a humidified 
chamber. These included mouse monoclonal anti-ED1 (AbD Serotec, 1:100) for 
macrophage presence, rabbit anti-GFAP and mouse anti-chondrotin sulfate proteoglycan 
(Chemicon, 1:2000; Sigma, 1:200) for scar tissue formation, as well as mouse anti -RT97 
(neurofilament for host and graft axons, Chemicon, 1:1000) and rabbit anti-AP (only for 
grafted NRP/GRP cells, Accurate, Westbury, CT, 1:100) for host and transplant axon 
growth.  Tissue sections were then washed in PBS followed by incubation in the dark for 
2hrs at room temperature in their secondary fluorescent antibody. All secondary 
 150 
antibodies were used at 1:200 (Jackson Laboratories) with 2% goat serum. Sections were 
again rinsed with PBS and coverslipped with vectashield hardest mounting media (Vector 
Labs) and stored flat at 40C until imaged. All images were taken using a Leica DM5500 
fluorescent microscope (Leica Microsystems, Bannockburn, IL). 
Another series of slides was used to quantitate the presence of macrophages after 
grafting. Briefly, after blocking and incubation with the primary antibody as described 
above slides were washed with PBS, followed by incubation in a biotinylated goat anti-
mouse IgG (1:100, Vector Labs, Gold label) with 1% goat serum for two hours in a 
humidified chamber at room temperature. The slides were again washed with PBS 
followed by incubation in the ABC reagent (Vector Labs) for 2 hours in a humidified 
chamber at room temperature. Slides were then rinsed with PBS and 0.05M Tris-HCl 
(Fisher, pH 7.6) prior to reacting the ABC reagent with 3-3’ diaminobenzidine 
tetrahydrochloride (DAB, Sigma) as per manufacturer’s instructions. The tissue was then 
washed with distilled water, dried, dehydrated and coverslipped with DPX. 
 
6.2.8 Image Analysis 
 Quantitative image analysis was done on ED-1 slides as well as 
Nissl/myelin stained slides for the amount of macrophages present and injury size, 
respectively. Image analysis was done using NIH Image software (National Institute of 
Health), and tracing the size of the injury, and cysts as compared to the total cord volume, 
as calculated by the Calvieri’s estimator of volume (equation 5.1), where A is the area of 
each tissue section, D is the distance between measurements, Amax is the area of the 
largest section, and ytissue is the thickness of each section. 
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6.3 Results & Discussion 
6.3.1.   Is the PNIPAAm-PEG scaffold surgically realizable? 
 To test the surgical realizability of the PNIPAAm-PEG scaffold, at 10-wt% 
aqueous copolymer solution was injected into a partial hemisection rodent injury model.  
A picture of one of these injections can be seen in Figure 6.1. Since injection volumes 
were so small (3-5uL), injection of the viscous solution without entrapping air bubbles 
proved difficult. The small gauge needles necessary for injection into the small injury site 
were not compatible with the viscous solution, and therefore physical displacement 
pipettes were used for all injections  in the four-week survival study.  
During injection, the PNIPAAm-PEG solution transition was highly succeptable 
to the ambient room temperature. When the room was warmer, the solution began to 
transition during the injection, however, when the room was cold, the solution did not 
transition until the dura was sutured and the skeletal muscle was placed back over the 
injury.  This early transitioning is because the transition temperature (LCST) of the 
PNIPAAm-PEG copolymer is around 310C, meaning it is very close to room temperature. 
The surgical conditions could be optimized by either increasing the LCST of the polymer 
or cooling the spine of the animal. 
The scaffolds ability to be space filling and remain in the injury site was 
determined using the Nissl/Myelin histology on sections around the injury site.  An 
example of a PNIPAAm-PEG gel in the injury for four weeks can be seen in figure 
6.1(B). The scaffold was able to mold to the injury site as expected, and was able to 
remain intact through perfusions, sectioning and histology. During injection, however, it 
appears that some spinal fluid interrupted the transitioning gel creating cysts that are seen 
 153 
throughout the study. It is proposed that a solution to this would be to decrease the 
viscosity of the polymer, to improve the ability to control the injection through the fine 
gage needle. Another possibility would be to inject directly into the tissue to prevent fluid 
intrusion, or to inject serially over several minutes, allowing the prior injection to 
transition before adding the next. This method would ensure the entire cavity would be 
filled with the scaffold prior to suturing.  
In order to compare the space filling ability of the PNIPAAm-PEG scaffold with 
what is commercially available, a short study was done were animals were sacrificed two 
weeks post injection of one of the following: PNIPAAm-PEG, Vitrogen or Gelfoam. 
Nissl/Myelin histology (figure 6.2) shows that the Gelfoam scaffold has already degraded 
leaving a large cyst at the injury site. The Vitrogen scaffold, similar to the PNIPAAm-
PEG remains space filling, but also is suceptable to fluid cysts. Since the Vitrogen 
scaffold is a collegen based biopolymer, it is possible that the fluid cysts are created due 
to swelling of the scaffold in vivo post implantation.  
 
6.3.2. What is the host response to the PNIPAAm-PEG scaffold? 
 In the spinal cord, along with a classic foreign body response to an implant, there 
is already an inflammatory response (increase in fluid as well as macrophages to the local 
area) to the injury as well as an upregulation of growth inhibitory molecules and the 
formation of a glial scar11. The glial scar is a combination of cell debris, myelin, 
astrocytes, oligodendrocytes and microglia. The scar formation is a major physical barrier 
to the reconnection of neural processes (mainly axons) with their targets11. The goal of a 
biomaterial implant within the spinal tissue then must be to not only elicit minimal 
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inflammatory response as indicated by the presence of macrophages (ED-1), but also to 
reduce or at minimal not increase the formation of the glial scar12-14. The presence of 
fluid cysts after the macrophage invasion of the injury site is also an impedence to 
biochemical signal pathways in the spine11, so materials implanted into the spine should 
not create more cysts than already found after an injury, rather should aim to prevent the 
formation of any cysts.  
 In order to assess the host response to the PNIPAAm-PEG scaffold, the animals 
were given one of the following injections: PNIPAAm-PEG alone (gel), gel + 
neurotrophic factors (NTF’s), gel + NTF’s + marrow stromal cells (MSC), gel + NTF’s + 
neural precursor cells (NPC) or gel + NPCs. Since the multifunctional scaffold design 
proposed is to include cells and trophic factors with the scaffold, it was important to 
assess the affect of each all components on the host response.  
The animals were sacrificed after four weeks, and sections were immunostained 
with ED-1 macrophage marker. The staining of the ED-1 shows the presences of an 
inflammatory response to the injury, which is a common response in all SCI. This study 
was to assess if the presence of the biomaterial along with the cells and trophic factor had 
an affect on the amount of macrophage response detected.  A representative image from 
each set of injections can be seen in figure 6.3. Each ED-1 slide is shown next to a nearby 
section stained with Nissl/Myelin to show the relative morphology of the injury site. It is 
clear that the scaffold alone does not elicit a large inflammotry response after four weeks, 
however, the addition of the neurotrophic factors (BDNF and NT-3 at 50 ug/mL) 
increases the response. The inclusion of foreign cells creates the largest macrophage 
response.  This is not a surprising results, since the cells are recognized as foreign to the 
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host immune system, however, the limited response to the PNIPAAm-PEG gel is an 
excellent result for the biocompatibility of this scaffold design. 
 Along with the inflammatory, another host response to the injury site is the 
formation of the glial scar created mainly by reactive astrocytes and microglia. This scar 
tends to create an impermeable boundary for the remaining neural tissue. It is important 
in further design of the scaffold to know what the host glial scar response is to the gel 
alone as well as the gel with neurotrophins and cells incorporated. The formation of the 
scar is best observed by immunostaining for glial-fibrillary acidic protein (GFAP) as well 
as chondrotin sulfate proteoglycan (CSPG). GFAP shows the presence of reactive 
astrocytes and CSPG is a protein believed to be involved in the formation of the glial 
scar. The results of this staining can be seen in figure 6.5.  It is clear that in all cases, 
CSPG and GFAP were present around the injury site  indicating the formation of a glial 
scar.  
 As a comparison to what is commercially available, a study was done with the 
PNIPAAm-PEG gel alone, Vitrogen, and Gelfoam in the same injury model with two 
week survival. Cross sections around the injury site were stained for GFAP and ED-1 
from this study and can be seen in figure 6.5. Comparison of these different scaffolds 
shows that the PNIPAAm-PEG scaffold does not elicit any greater host immune or glial 
scar response than does either commercially available product. 
 
6.3.3. Can the two cell types survive within the scaffold in vivo? 
 If the scaffold is to function as a cell transplantation device, it is critical that the 
grafted cells survive within the scaffold in vivo. Previous results from the in vitro studies 
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suggest that the two cells lines tested should be able to survive up to four weeks within 
the scaffold. To determine the viability of the MSC’s in vivo sections were immuno 
stained with anti-green fluorescent protein (GFP) since grafted cells were GFP+.  NPC 
survival was found using the AP histology described above. The results for both cell lines 
are shown in figure 6.6. It is clear from these results that the scaffold provides a 
compatible environment for the cells and allows the survival for up to four weeks in vivo. 
Since the assays were not done in such a way that could be quantified it is not clear how 
many of the cells remain, only that there are enough viable cells to be seen in the stain.  
 
6.3.4. Can axons grow in the scaffold? 
 Axon growth through the scaffold from either the host or grafted cells is one of 
the primary goals of this design. In order to assess the ability of the design to support 
axon growth, sections from the previously described four-week animal study were stained 
for neurofilament  (RT97). The results are shown in figure 6.7.  The absence of any axons 
in the scaffold alone is not a great surprise, since there was nothing present to attract or 
promote their growth present. However, the addition of NT-3 and  BDNF appears to 
increase the presence of axons around the scaffold, but alone does not produce axon 
growth in the scaffold. The addition of MSC cells with NT-3 and BDNF, does appear to 
have some increase in the amount of axons, and the most axon growth is seen in the NPC 
plus NT-3 and BDNF scaffold. A closer comparison of the NPCs with and without 
neurotrophic factors added is shown in Figure 6.8. Included here is also the AP histology 
of the closest tissue section showing the presence of the NPCs. From these results the 
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presence of trophic factors appears to have much less influence on the promotion of axon 
growth than the presence of the transplanted NPCs.  
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Animal #'s PNIPAAm-PEG NT-3 /BDNF Cells 
1,2,3,10,11,12 X X  
4,5,6,13,14,15 X X NPC's (AP+) 
7,8,9, 16,17,18 X X MSC's (GFP+) 
19-24 X   NPC's (AP+) 
25-30 (control) X     
 
 
Table 7 Experimental matrix for animal surgeries. The different groups (n=6 each) for 
the rodent surgeries are explained in the above table. All references to “gel” are 
PNIPAAm:PEG, (8000) 735:1 monomer ratio, 10 wt% aqueous solution made in 
DMEM/F12 media with fetal bovine serum. 
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Figure 39 Surgical feasibility of PNIPAAm-PEG scaffold.  Part (A) shows the 
injection of the scaffold into the partial cervical hemi section, while part (B) shows the 
injury histology two weeks post surgery.  
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Figure 40 Scaffold morphology in vivo.  The histological sections show the results two 
weeks post surgery of the implantation of three different types of polymeric scaffolds into 
a partial cervical hemi section. Part (A) and (B) are the commercially available 
Vitrogen and Gelfoam, while part (C) is the PNIPAAm-PEG scaffold. 
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Figure 41 Host response to different polymer scaffolds. Sections were immunostained 
for the macrophage marker (ED-1, red) and GFAP (green) for the detection of immune 
system invasion and glial scar formation, respectively. 
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Figure 42 Host response to PNIPAAm-PEG multifunctional scaffold. Sections were 
immunostained for the macrophage marker (ED-1) and are shown next to their 
corresponding histological results. 
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Figure 43 Glial scar formation.  Sections were immunostained for GFAP (green) and 
CSPG (red) which both indicate the formation of a glial scar.   
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Figure 44 Graft cell survival in vivo.  
 Detection of cell survival of the neural precursor cells was done using Alkaline 
phosphotase histology (since grafted cells were AP+). Marrow stromal cells were GFP+, 
so they were detected using an immunostain for anti-GFP.  
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Figure 45 Neurofilament (RT97) staining.  Sections were immunostained for RT97 
(neurofilament, red) as well as dual stained for the presences of cells in those applicable 
(hMSC and NPCs both green) to assess the ability of axons to grow in the multifunctional 
scaffold. 
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Figure 46 Affect of NT-3 and BDNF on NPCs. To determine the ability of NPCs to 
generate axons with and without the presence of NT-3 and BDNF (50µg/mL each) the 
NPC graft survival (AP histology) is compared directly to the immunostaining for RT97 
and AP for both groups of animals.  
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6.4 Conclusion 
 The results from the in vivo studies in this chapter show exactly as intended, a 
proof of concept for the design. Although these results are merely qualitative, and do not 
show any quantitative results, they are exciting and show promise for future more 
quantitative in vivo studies with PNIPAAm-PEG multifunctional scaffolds. The studies 
confirmed that the scaffold could be injected into an animal spinal cord injury model, and 
remained in the tissue up to four weeks post injury. The thermoresponsive scaffold was 
also able to withstand the perfusions, fixing, section and histology necessary to evaluate 
the host response. The scaffold was able to support the survival of two different cell lines 
in vivo for up to four weeks with and without the presence of NT-3 and BDNF.  The 
scaffold provided an adaptable enough matrix that the cells and axons could begin to 
grow through it. Since the results from these studies show only proof that the concept 
works, and not a quantitative extent, further more detailed studies need to be pursued.  
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Chapter 7  Future Recommendations 
 
 
 
7.1 Future recommendations for PNIPAAm-PEG scaffolds for 
spinal cord repair 
 
This work has shown that a multifunctional, injectable scaffold can be developed to 
match the desired material properties of the native neural tissue in vitro. The polymeric 
scaffold has also been shown to support cellular growth and attachment in vitro, as well 
as provide a controlled release of biologically active trophic factors (namely BDNF and 
NT-3) for up to 4 weeks, and projected to 6 weeks. Qualitative assessments of the 
scaffolds in vivo biocompatibility and surgical realizability showed the scaffold could be 
injected and retained within the injury lesion. The scaffold could incorporate two 
different cell lines that remained within the scaffold for four weeks in vivo post 
implantation. The scaffold did not qualitatively elicit a large macrophage response, nor 
did it appear to have an increased glial scar formation. Therefore the next logical steps in 
this project are to further investigate the in vivo properties of the scaffold in a more 
quantitative study. The animal model should include a study of the host tissue as well as 
the graft cell interaction with the scaffold. Behavioral studies should be done in order to 
assess the functional recovery ability of the scaffold.  
Although the scaffold does exhibit an extended controlled release of therapeutic 
proteins, the bioactivity assay should be repeated at lower concentrations. The 
concentrations of BDNF and NT-3 used in this study were set high to match the dosages 
used in the in vivo studies. These concentrations, however, only require that 0.1% of the 
released protein remain bioactive for a response to be seen from the DRG explants. A 
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similar study needs to be repeated in which the concentrations are either kept the same 
and then further diluted prior to incubation with the DRG explants or set to a lower 
concentration to start with (beginning at 1 µg/mL instead of 50 µg/mL).  
Further modifications and optimization of the polymeric system are also highly 
advisable. The polymer scaffold tends to “shrink” upon gelation because it expels a large 
amount of water, causing difficulty in surgically injecting the scaffold while keeping it 
space filling. One proposed method to overcome this problem is to perform serial 
injections over several minutes, allowing each prior injection to completely transition 
before starting the next. This should allow the scaffold to completely fill the injury site 
prior to suturing of the dura. 
 
7.2 PNIPAAm-PEG scaffolds for other tissue engineering 
applications 
Tissue engineering is a rapidly expanding field of researching with over 3.5 billion 
dollars in R&D expenditures since 1990, leading to the formation of Multi-Agency Tissue 
Engineering Science working group (MATES). Some of the participating members of 
MATES include the National Science Foundation, National Institute of Health, and 
Department of Defense. With a five-year strategic plan to facilitate collaborative research 
efforts to advance the field of tissue engineering, a vast number of funding sources are 
available for academic research.  Polymeric scaffold systems are of great interest in many 
different tissue-engineering applications, and in most cases the traditional, non-injectable 
scaffold is being investigated. Using this injectable platform, or even other injecatable 
natural polymer systems, could be of great interest in many areas such as cartilage 
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regeneration, cardiac and vascular tissue replacement, and wound healing. Combing the 
drug delivery via biodegradable microparticles and cellular transplant with these injectable 
scaffolds makes these designs a novel multifunctional platform. The interaction of 
precursor cell transplants as well as native host cells with the biomaterials is of great 
importance in tissue engineering designs. Some grants this research could be applied to 
include; NIH R01 Enabling Technologies for Tissue Engineering and Regenerations, 
NSF- Bioengineering, NSF- Biomaterials, Craig Neelson Foundation, Christopher 
Reeves Foundation and the NSF- Career Development Award to Promote Diversity in 
Neuroscience Research.  
 
7.3 Microparticle sterilization  
Although a vast number of polymers are currently under investigation for biomaterial 
applications, very few ever make it to in vivo animal studies, especially in microparticle 
formulations. A large problem in moving materials toward cellular and in vivo studies is 
the inability to sterilize the biodegradable or thermosensitive polymers without damaging 
the polymer itself. Common sterilization techniques include steam sterilization 
(autoclaving), electron beam, and exposure to either ethylene oxide (EtO) or ethanol-
water mixtures. Commonly used biomaterials such a poly(lactic acid), PLA, are sensitive 
to all of these methods and would resulting in either a melting of the polymer or a 
premature release of the therapeutic agent. Recent literature has suggested that the 
exposure of such materials to supercritical CO2 sterilizes the polymer with minimal 
effects on the structure of the polymer.  Exposure post processing of the PLA 
microparticles could therefore potentially sterilize the microparticles without damaging 
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their structure or releasing the entrapped therapeutic agent. Although results found in this 
research saw that sterilization attempts post-fabrication melted the PLA, novel methods 
where microparticles are formed with the supercritical CO2 as one of the emulsion phases 
are proposed as an exciting alternative. 
 
7.4 Targeted microparticle designs 
 Although after much time and effort optimizing a microparticle delivery system 
for protein therapeutics, it was found that the use of microparticles for the release 
requirements in spinal cord repair was unnecessary. The result that the scaffold alone, 
originally thought to be the experimental control, provided a controlled release for 4-6 
weeks was somewhat disappointing after the exciting results achieved with the micro 
encapsulation efforts (Chapter 3).  These microparticles, however, can still see use in 
spinal cord repair. Although mechanical stabilization, and filling of the injury lesion with 
the multifunctional scaffold are the first step, additional cues and chemical signals are 
necessary both above and below to the injury site. It is proposed that through the injection 
of microparticles into the uninjured spinal tissue, both above and below the injury site, 
the additional cues necessary to see regenerated axons grow not only in the scaffold, but 
back out the other side. 
 In order to effectively promote the growth of these axons, a variety of therapeutic 
agents can be loaded into the microparticles. The creation of gradients of these 
therapeutic agents is thought to be the most promising technique for guiding the growing 
cells in the direction of their targets. This can be achieved through the injection of these 
microparticles at several locations throughout the spine. The concentrations of 
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microparticles, as well as therapeutic agent in the microparticles can be varied to aid in 
the formation of the gradient. The ratio of lactide:glycolide used in the production of the 
microparticles can also be varied in an effort to tailor the release of the different 
therapeutic agents. 
 The microparticles can also be designed to target specific sites, such as chondrotin 
sulfate proteoglycan (CSPG), a protein known to aide in the formation of the glial scar. 
Once the microparticle then attaches to the CSPG, it can slowly release over time 
chondrotinase (an enzyme to degrade CSPG) and hopefully prevent some of the glial scar 
formation. The targeting of the microparticles to the CSPG can be achieved by the 
addition of the antibody to CSPG to the surface of the microparticle. This can be done by 
using a PLA-PEG based polymer system, that would ensure the PEG side would always 
be on the outer surface of the particle (since the hydrophilic polymer would be drawn to 
the larger secondary aqueous phase during processing). Reaction chemistry with PEG is 
very well established, and should allow the attachment of a biotin molecule. This biotin 
molecule has a high affinity for avidin, which could then be linked to the anti-CSPG. 
Using a robust linkage system such as this allows for the transition to different targets 
with minimal effort.  
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